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ABSTRACT OF DISSERTATION
Metabolic Regulation of CD8 T cell Function in the Tumor Microenvironment
By
Jing Qiu
Doctor of Philosophy in Biology and Biomedical Sciences (Immunology)
Washington University in St. Louis, 2017
Professor Erika L. Pearce, Professor Paul M. Allen, Co-Chairperson

Failure of T cells to protect against cancer is thought to result from lack of antigen
recognition, chronic activation, and/or suppression by other cells. Using a mouse
sarcoma model, we show that glucose consumption by tumors metabolically restricts
T cells in the tumor microenvironment, leading to their dampened mTOR activity,
glycolytic capacity, and IFN-γ production, and thereby allowing tumor progression.
We demonstrate that enhancing glycolysis in an antigenic ‘regressor’ tumor is
sufficient to override the ability of T cells to respond to a major tumor rejection
antigen, allowing progression of tumors that are normally rejected. Checkpoint
blockade therapy is used clinically to promote immune rejection of progressing
tumors. We show that checkpoint blockade (anti-CTLA-4, anti-PD-1, and anti-PD-L1)
monoclonal antibodies (mAbs) restore glucose in the microenvironment of
progressing tumors, permitting T cell glycolysis and IFN-γ production. Furthermore,
we unexpectedly found that blocking PD-L1 directly on tumors dampens glycolysis
by inhibiting mTOR activity and decreasing expression of glycolysis enzymes. These
data reflect a novel role for PD-L1 in tumor glucose utilization. Together our results
establish

that

tumor-imposed

metabolic

X

restrictions

can

mediate

T

cell

hyporesponsiveness during cancer and suggest that checkpoint blockade therapy
may be targeting this mechanism.

Glucose has been viewed as a major carbon source for adenosine triphosphate
(ATP) generation, which is not only essential for the maintenance of cellular
bioenergetics, but also critical for the regulation of effector T cell function. Consistent
with the model that glucose consumption by antigenic tumors can metabolically
restrict infiltrating T cells (TILs) and directly dampen their cytokine production,
leading to tumor progression, it is conceivable that supplementation of glucose may
rescue T cell hyporesponsiveness as a result of nutrient depletion. However,
resupplying TILs with glucose ex vivo does not fully restore cytokine production,
indicating that mechanisms beyond substrate limitation contribute to loss of effector
functions in TILs. Exactly how T cells reprogram their metabolism in a nutrient
restricted microenvironment and how this influences their effector functions remains
unclear. In the second part of this study, we focus on understanding the metabolic
alteration of T cells experiencing long-term glucose restriction. We found that T cells
deprived of glucose lose responsiveness to exogenous glucose over time. Their
inability to acquire glucose and thus engage glycolysis contributes to a
hyporesponsive state characterized by impaired cytokine production. However,
glucose restricted T cells remain responsive to acetate, which is the substrate for
acetyl coenzyme A (acetyl-CoA) synthesis and thus is positioned at the intersection
of metabolism and genetic regulation. The rescue of effector cytokine production of T
cells by acetate supplementation was dependent on the nuclear-cytoplasmic acetylCoA synthetase enzyme (ACSS2). Our results demonstrate an alternative metabolic
pathway engaged by T cells in a dearth of glucose. Combining therapies that blunt

XI

tumor metabolism with those that promote glycolysis in T cells or distinct metabolic
pathway triggered by alternative metabolites that directly regulate cytokine gene
expression may generate more effective T cell based immunotherapies in the
context of human disease including cancer.
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CHAPTER 1

T CELL METABOLISM AND IMMUNITY

1

§ 1.1 Introduction

An effective adaptive immune response is initiated when naïve T cells encounter
foreign antigens in the form of peptides presented by MHC molecules on
professional APCs and become activated. In the context of appropriate costimulation
signals, T cells will transition to a period of rapid clonal expansion, producing a
variety of effector molecules that lead to the elimination of the pathogen. To support
their activation, clonal expansion and exertion of effector functions, T cells must
undergo metabolic reprogramming to shift from a quiescent phenotype generating
energy by oxidative metabolism to a predominantly anabolic and intermediary
metabolism that requires a high nutrient flux into the cells (Vander Heiden et al.,
2009, van der Windt and Pearce, 2012, Wang and Green, 2012, MacIver et al.,
2013, Pollizzi and Powell, 2014). Upon pathogen clearance, most effector T cells
undergo apotosis, leaving behind a small proportion of long-lived antigen specific
memory T cells that can respond to antigens quicker and stronger in the future.
Consistent with their distinct characteristics, memory T cells must also reprogram
cellular metabolic pathway to support their differentiation, longevity and “rapid recall”
ability (van der Windt et al., 2012). As a result, engaging in a proper metabolic
pathway is required for a protective T cell immune response.

Metabolism fundamentally underpins T cell functions. The processes of cellular
activation, differentiation and massive proliferation are unique aspects in T cell
biology compared to most terminal differentiated healthy cell types, thus there is
great interests in understanding how metabolic pathway support vigorous changes in
cellular activities, influences immune response and ultimately dictate disease
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progression. Combination of modern tools for analyzing and tracing these cells both
in vitro and in vivo make it suitable for exploring this complex network of
biochemistry

reaction

biosynthesis,

especially

involved
the

in

energy

molecular

production

mechanisms

and

that

macromolecular

govern

metabolic

reprogramming in the immune system (Wang and Green, 2012, Pearce and Pearce,
2013). In addition, each step of these metabolic modifications that happen during
the normal T cell development is intimately linked to the cell fate and function, which
represents potential points for clinical intervention. The ability of eliciting or
enhancing desired T cell response may assist in controlling or at least mitigating
multiple diseases including infections, cancers and autoimmune disorders. As a
result, targeting these cells by manipulating their metabolism hold promise for
developing novel therapies to improve human health (Finlay and Cantrell, 2011,
Wang and Green, 2012, Pearce and Pearce, 2013, Pearce et al., 2013).
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§ 1.2 The dynamics of T cell metabolism

Glucose is a critical substrate for adenosine triphosphate (ATP) production (Greiner
et al., 1994), which supports cellular bioenergetics in all living cells, including T
lymphocytes. During the course of glycolysis, glucose is broken down into two
molecules of pyruvate, generating two reduced nicotinamide adenine dinucleotide
(NADH) molecules and two net ATP molecules per molecule of glucose. This
process dose not require the participation of oxygen. In case of terminally
differentiated, nonproliferating cells, pyruvate can be completely oxidized in the
tricarboxylic acid (TCA) cycle, yielding NADH and reduced flavin adenine
dinucleotide (FADH2) to fuel oxidative phosphorylation (OXPHOS), which is a
oxygen dependent process generating up to 36 molecules of ATP per glucose
molecule. On the other hand, pyruvate can be fermented into lactate in an oxygen
independent process termed aerobic glycolysis, regenerating NAD+ for subsequent
use. Notably, only two molecules of ATP are gained per molecule of glucose via
aerobic glycolysis. From a bioenergetics perspective, engaging OXPHOS maximizes
the amount of ATP that can be derived from glucose (Vander Heiden et al., 2009).

Bioenergetic profiling of T cells has revealed that T cell metabolism changed
dynamically with the activation state. Resting naïve T cells have a metabolically
quiescent phenotype, which metabolize glucose, fatty acid and amino acids to
generate reducing equivalents that fuel oxidative phosphorylation (OXPHOS) in the
mitochondria (Yusuf and Fruman, 2003, Fox et al., 2005, van der Windt et al., 2012).
Upon activation, highly proliferative effector T cells augment aerobic glycolysis, a
mitochondrion-independent metabolism of glucose in the cytoplasm although
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sufficient oxygen is present to utilize OXPHOS. Although aerobic glycolysis is less
efficient when ATP is generated in this pathway, it may afford a metabolic advantage
not only allows for rapid ATP production in effector T cells in favor of glucose replete
environment but also supplies various metabolites for the synthesis of lipids, proteins
and nucleic acids, as well as provides a means for maintaining redox balance
(Anastasiou et al., 2011, Kidani et al., 2013). In addition, it has also been shown that
T cells can use either OXPHOS or aerobic glycolysis to survive and proliferate.
Instead, they need to engage aerobic glycolysis for the acquisition of full effector
function via a posttranscriptional mechanism (Cham and Gajewski, 2005, Cham et
al., 2008, Chang et al., 2013, Pearce et al., 2013). In the absence of this glycolytic
flux, the glycolysis enzyme GAPDH acts as an RNA-binding protein, binding to and
inhibiting the translation of effector cytokine mRNA (Chang et al., 2013). Glutamine
also presents as another essential carbon source for TCA cycle in form of αketoglutarate through the process of glutaminolysis, or can contribute to the citrate
pool via reductive carboxylation. Deletion of glutamine or glucose transporters
impairs T cell activation and function (Carr et al., 2010, Metallo et al., 2011, Sinclair
et al., 2013, Macintyre et al., 2014).

Several signaling pathways and transcriptional factors tightly control the metabolic
transition T cells experience after activation. The recognition of peptide-MHC
complex by the T cell receptor (TCR) with CD28 costimulation triggers the activation
of Phosphatidylinositol 3 Kinase (PI3K), AKT and Mechanistic Target of Rapamycin
(mTOR) signaling pathways, and increased surface trafficking of the glucose
transporter Glut1 (Rathmell et al., 2003, Jacobs et al., 2008, Powell et al., 2012,
Macintyre et al., 2014). mTOR is a serine/threonine kinase comprised of two protein
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complexes—mTORC1 and mTORC2—has a fundamental role in coordinating
anabolic and catabolic processes associated with nutrient levels, energy status, cell
stress response, as well as growth factor signaling (Duvel et al., 2010, Laplante and
Sabatini, 2012). Opposing mTOR is the 5’ AMP-activated protein kinase (AMPK),
which acts as a metabolic stress sensor and promotes oxidative metabolism (Tamas
et al., 2006, Blagih et al., 2015). Transcriptionally, metabolic reprogramming in
activated T cells is driven by the expression of the transcription factors Myc and
hypoxia inducible factor 1α (HIF-1α) (Wang et al., 2011, Finlay et al., 2012, Doedens
et al., 2013, Sullivan et al., 2013, Tannahill et al., 2013). Myc regulates cell cycle
progression by controlling the expression of several essential cell cycle regulators
both directly and indirectly. It has been shown that maximum expression of Myc is
required for the induction of enhanced glycolysis activity following T cell activation
(Wang et al., 2011). HIF-1α is another transcriptional factor that actively shunts
glucose metabolism from OXPHOS in the mitochondria to aerobic glycolysis to
maintain ATP production and prevent toxic ROS generation in oxygen depleted
environments, protecting cells from hypoxia-induced apoptosis (Doedens et al.,
2013, Sullivan et al., 2013, Tannahill et al., 2013). Collectively, these factors that
promote glycolytic gene expression and posttranscriptional regulation are essential
to enforce effector T cell metabolism and function.

In contrast to effector T cells, memory T cells adopt a metabolic profile similar to that
of naïve T cells, which is using a catabolic metabolism characterized by increased
reliance on OXPHOS and lower rates of nutrient uptake (O'Sullivan et al., 2014).
However, memory T cells maintain substantial spare respiratory capacity (SRC) and
have increased mitochondrial mass, both of which confer a metabolic advantage for
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survival and recall when re-encountering pathogens (van der Windt et al., 2012, van
der Windt et al., 2013). SRC is the maximal respiratory capacity reserved for cells to
generate more energy and promote cell viability under increased stress or nutrient
limitation (Yadava and Nicholls, 2007, Nicholls, 2009). From this vantage, memory T
cells maybe viewed as being metabolically primed, with mitochondrial metabolism
fueling the rapid recall response to reinfection. The memory T cell promoting
cytokine interleukin (IL)-15 plays a key role in this catabolic switch by promoting
mitochondrial biogenesis (van der Windt et al., 2013).

The machinery controlling the differentiation of T cells from effector to memory states
are still not clear, but recent studies suggest that transitions in metabolism may play
a role in this process. For example, mitochondrial FAO has been demonstrated to
stimulate downstream of tumor necrosis factor (TNF) receptor-associated factor 6
(TRAF6), which is required for memory CD8+ T cells development (Pearce et al.,
2009). Attenuation of aerobic glycolysis or the enhancement of OXPHOS can alter T
cell phenotype dramatically. For example, rapamycin or AMPK activator metformin
induced augmentation in catabolic pathway can eliminate the differentiation of CD8+
T cells but enhance development of CD8+ memory T cells (Pearce et al., 2009).
Similarly, the inhibition of mTOR by rapamycin or blockage of glycolysis by
hexokinase inhibitor 2-deoxyglucose (2-DG) can block the differentiation of T helper
17 (Th17) cells while promoting regulatory T (Treg) cell development (Kopf et al.,
2007, Michalek et al., 2011, Shi et al., 2011). Moreover, enhancement of fatty acid
oxidation (FAO) and energy conservation by activating AMPK pathway also tips the
balance of CD4+ T cell differentiation in favor of Treg (Hardie et al., 2012). Given
these observations, memory T cell formation maybe influenced by a number of
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enzymes and transporters involved in fatty acid synthesis, desaturation and
oxidation, as well as availability of free fatty acids (FFA) to memory precursor cells.
For instance, acetyl-CoA carboxylase (ACC2), the mitochondrial lipid transporter
CTP1A, and the metabolites such as acetyl-CoA, malonyl-CoA has been considered
as important players in this process (Abu-Elheiga et al., 2001, Deberardinis et al.,
2006, van der Windt et al., 2012). AMPK activation and mTOR inhibition are also
both potent activators of autophagy, a catabolic process induced during starvation
that has been shown to be important for the maintenance of cellular bioenergetics
and sustained T cell viability after activation (Kundu and Thompson, 2008, Hubbard
et al., 2010).
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§ 1.3 Metabolic regulation and T cell function

T cell metabolism changes over the course of an immune response. Naïve T cells
are metabolically quiescent, which adopt a basal level of nutrient uptake and use
OXPHOS as their primary pathway for ATP generation. Upon immune challenge,
effector T cells switch to a statue of metabolic activation featured by increased
nutrient uptake, elevated glucose and glutamine metabolism, biomass accumulation
and reduced mitochondrial SRC. Effector T cells preferentially engage in glycolysis
for ATP production. Transition from effector to memory T cells is characterized by a
quiescent metabolism dependent on FAO to fuel OXPHOS. However mitochondrial
mass and SRC are reserved in memory T cells, suggesting that these cells are
metabolically primed to respond upon reinfection.

As described before, the ability to engage in glycolysis plays an essential role during
T cells activation. Recent evidence indicates that mitochondrial OXPHOS is also
important for T cells transiting from naïve to effector state. Blocking mitochondrial
ATP synthase by oligomycin can block the expression of early activation markers
after TCR ligation and blunts subsequent T cell proliferation (Chang et al., 2013).
Mitochondrial derived reactive oxygen species (ROS) may function as a
bioenergetics secondary messenger in shaping T cell response (Chaudhri et al.,
1986, Devadas et al., 2002, Jackson et al., 2004). T cell deficient for ubiquinolcytochrome c reductase (Uqcrfsl), a component of complex III of electron transport
chain (ETC), displays impaired TCR-dependent ROS production and defects in
antigen-specific proliferation (Sena et al., 2013). Intracellular calcium (Ca+) flux,
which happens early in TCR signal transduction, may also indicates a intimate link
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between TCR ligation, mitochondrial OXPHOS, and cell proliferation because of the
evidence that uptake of Ca+ by mitochondrial could stimulate Ca+ dependent
dehydrogenases of TCA cycle, driving NADH as well as ATP production by
OXPHOS during early T cell activation (Krauss et al., 2001). T cells without Bax and
Bak, the apoptosis regulators important for Ca+ homeostasis exhibit reduced Ca+
dependent mitochondrial ROS production thus impair T cell proliferation after TCR
stimulation. Although toxic in many tissues, OXPHOS derived ROS may prime and
license full T cell activation.
Scientific advances in intermediate metabolism observed in cancer highlight a wealth
of evidences that are likely to be relevant to T cell biology. Many metabolic pathways
abnormally activated in cancer have been shown to play similar roles in normal
lymphocyte physiology. Take aerobic glycolysis for example, it has been described
as early as 1950s that tumor cells consume glucose at a high rate and produced
lactate in a process termed the “Warburg effect” (Warburg, 1956). Proliferating T
cells engaged in the same metabolic pathway which allow them to not only generate
ATP quickly but also metabolic intermediates important for supporting cell growth
and proliferation.

One of the key enzymes governing glycolytic flux and cell

proliferation is pyruvate kinase (PK). It catalyzes the terminal reaction of glycolysis
by promoting the conversion of phophsenolpyruvate (PEP) to pyruvate and is one of
two ATP-generating steps of glycolysis. There are two isoforms of PK and naïve T
cells express both of them (PKM1 and PKM2) in the resting state but preferentially
accumulate PKM2 when transiting to effector T cells (Marjanovic et al., 1990).
Interestingly, PKM2 is actually less efficient at converting PEP to pyruvate than
PKM1 but its expression is promoted in proliferating cells, including T lymphocytes.
Multiple lines of evidence point to a role of Warburg metabolism in supporting
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anabolic growth, in which enhanced PKM2 activity promotes the accumulation of
glycolytic intermediates towards upstream biosynthetic pathway to support amino
acid, triglyceride and nucleotide biosynthesis (Anastasiou et al., 2012, Kung et al.,
2012). Moreover, PKM2 also exert some of its effect on cell proliferation through
transcriptional and epigenetic regulation (Luo et al., 2011, Yang et al., 2012). PKM2
has been proved to phosphorylate signal transducer and activator of transcription 3
(STAT3) at Tyr705, promoting STAT3-dependent transcription (Gao et al., 2012). The
protein kinase activity of PKM2 can be viewed as a sensor to metabolic flux,
flavoring high glycolysis PEP conditions and antagonizing low-energy high ADP
concentration.

Another derivative from glycolysis as an anabolic precursor is 3-phosphoglycerate
(3GP), which is a key intermediate in both amino acid and nucleotide biosynthesis.
3GP is the starting point for the glucose-dependent biosynthesis pathway of serine
and glycine via serine biosynthesis pathway (SBP). Key enzymes involved in SBP
are phosphoglycerate dehydrogenase (PHGDH) and serine hydroxymethyltrasferase
(SHMT), generating glycine and methylene-THF to fuel downstream nucleotide
biosynthesis and methylation reaction. Serine is also an allosteric activator of PKM2
(Chaneton et al., 2012) and thus provides feedback to the glycolytic pathway to
regulate 3PG levels and serine biosynthesis. The amplification of PHGDH that can
enhance flux through SBP may confer a growth advantage to proliferation cells by
generating NADH to fuel mitochondrial OXPHOS for making ATP. The conversion of
3-phosphohydroxypyruvate to 3-phosphoserine by phosphoserine aminotransferase
(PSAT) requires glutamate and α-KG, thus SBP may indirectly promote alternative
pathway of α-KG as well as its dependent enzymes activity (Possemato et al., 2011).
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Furthermore, recent study indicates production of reduced glutathione (GSH) derived
from serine and glycine via SBP can be used as a buffer against oxidative damage
(Maddocks et al., 2013). Together, it makes more sense that proliferating effector T
cells actively engage in SBP upon activation regardless of abundant exogenous
serine.

Similar to glycolysis, TCA cycle in proliferating cells functions as a source of
biosynthetic precursors in addition to its role in ATP production (DeBerardinis et al.,
2008). Glucose derived pyruvate that is not converted to lactate will enter
mitochondrial and be converted into acetyl-CoA by pyruvate dehydrogenase (PDH)
complex. Together with rate-limiting substrate oxaloacetate (OAA), glucose-derived
acetyl-CoA generate citrate in the TCA cycle, which is essential in lipid biosynthesis.
CD8+ T cells unable to engage this acetyl-CoA-dependent lipid biosynthetic pathway
display defect in antigen-driven blastogenesis and clonal expansion in response to
pathogens (Kidani et al., 2013). Another key metabolite generated through TCA
cycle is α-KG from glutamine via glutaminolysis. Groundbreaking work indicates that
α-KG can be converted to citrate through reductive carboxylation under conditions of
stress such as hypoxia or mitochondrial dysfunction, which bypasses the
conventional TCA cycle by using glutamine to generate acetyl-CoA for fatty acid
synthesis (Metallo et al., 2011, Mullen et al., 2011, Wise et al., 2011). This
alternative pathway for lipogenesis implicates the possibility that T cells are able to
use reductive glutamine for fatty acid biosynthesis under hypoxic condition (Metallo
et al., 2011). Such metabolic plasticity prepares T cells to response to environmental
cues and in order to maintain proliferation and /or effector function.
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In mammalian cells, fluctuations in cellular energy are monitored by heterotrimetric
AMPK complex, which contains nucleotide-binding sites of the γ regulatory subunit
that binds ATP, ADP or AMP.

Elevation of cellular AMP:ATP ration leads to

increased phosphorylation of AMPK at Thr172 of its activation loop through the
kinase LKB1, which make AMPK functions as a sensor for cellular energy charge
(Oakhill et al., 2011, Xiao et al., 2011, Hardie et al., 2012). Together with LKB1,
AMPK promote catabolic pathway for ATP generation and antagonized mRNA
translation through negative regulation of mTORC1 (Shackelford and Shaw, 2009).
Recent work suggests that LKB1-AMPK signaling can influence T cell metabolism
and function. Lymphocytes exclusively express the α1 subunit of AMPK indicating its
role in promoting catalysis. TCR engagement promote LKB1 dependent AMPK
activation while in turn lost of LKB1-AMPK signaling enhance glycolysis as well as
mTORC1 activity with elevated TH1 cytokine interferon-γ production by effector T
cells (Tamas et al., 2010, MacIver et al., 2011, Faubert et al., 2013). Deletion of
either LKB1 or AMPK α1 disrupts normal lymphocytes homeostasis, leading to an
accumulation of activated CD8+ T cell population in animals (MacIver et al., 2011).
Furthermore, it was recently shown that AMPK-deficient T cells are defective in
generating CD8+ memory T cells during infection (Rolf et al., 2013). In summary,
AMPK may serve as a metabolic checkpoint in T cells to regulate its metabolic
fitness and immune functions coordinating metabolic change in response to nutrient
fluctuation in the microenvironment.

All in all, the implication of these findings for immunologists is that we may gain
control over cell growth and survival by directly influencing metabolic currency of
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cells, energetic intermediates and metabolites involved in bioenergetics and
biosynthetic reactions through metabolic reprogramming.
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§ 1.4 T cell dysfunction in tissue microenvironment

T cells are influenced by nutrients and other supportive signals, such as those
provided by growth factor cytokines, which are available in their environment. In
settings such as chronic infection and cancer, T cells can become anergic, or
exhausted, losing the capacity to exert their effector function thus leading to disease
progression. Take cancer for example, one of the primary mechanisms of T cell
dysfunction is thought to be long-lasting stimulation from immunogenic antigens
expressed by tumor cells. Chronic TCR stimulation, lack of proper costimulation,
and active suppression by other cell types in the tumor microenvironment has all
been implicated in T cell dysfunction (Wherry, 2011, Crespo et al., 2013, Pauken and
Wherry, 2015).

Evidences in gene expression analysis of exhausted T cells

indicates that several genes involved in energy metabolism transcriptionally
downregulated and inhibiting leucine or glucose metabolism during T cell activation
can lead to an anergic phenotype (Zheng et al., 2009, Wherry, 2011). Moreover,
upregulated expression of inhibitory receptors on exhausted T cells, such as
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death
protein-1 (PD-1) has been shown to inhibit elevated glucose and glutamine
metabolism induced by TCR ligation and co-stimulation during T cell activation
(Parry et al., 2005, Boussiotis et al., 2014). Especially, ligation of PD-1 through its
ligands PDL-1 can alter T cell metabolic reprogramming by inhibiting glycolysis and
promoting lipolysis and fatty acid oxidation (Patsoukis et al., 2015). This metabolic
alteration regulated by PD-1 contributes to bioenergetics insufficiencies through
mTOR signaling thus presents as an early driver of CD8 T cell exhaustion (Bengsch
et al., 2016). All these findings implicate that T cell hyporesonsiveness may be in
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large part due to an inability of the cells to optimal utilize appropriate metabolic
pathway.

Nutrient competition between cells can influence cell growth, survival, and function –
and a fierce competition likely exists between cells in the tumor microenvironment,
as the demand for resources is high (MacIver et al., 2013, Siska and Rathmell,
2015). Tumor cells promote Warburg metabolism over oxidative metabolism for
quick ATP generation to support their rapid cell growth, so do proliferation T cells.
We speculate that lymphoid organs where lymphocytes resides and activated are
nutrient-replete and normoxia but high level of glycolytic activity in cancer cells
coupled with poor angiogenesis can lead to glucose depletion and accumulation of
lactate in the local tumor sites infiltrated by T cells. Nutrient availability in the tumor
microenvironment can post particular metabolic challenges for antitumor T cell
responses. For example, tumor cells can express indoleamine 2,3-dioxygenase
(IDO), an enzyme that depletes tryptophan from the microenvironment and thus
inhibits T cell proliferation and effector function (Munn et al., 1999, Munn and Mellor,
2013). Tumor-derived lactate can also suppress T cell function directly by
suppressing lactate export from T cells, thus disrupting their ability to maintain
glycolysis (Fischer et al., 2007). Metabolic interaction between tumor cells and
immune cells in metabolic restrictive environment may present a potential
mechanism of T cell hyporesponsiveness during cancer. Because glucose and
glutamine are crucial for T cell differentiation and function, and depletion of glucose
impairs cytolytic activity as well as IFN-γ production (Chang et al., 2013). Culture of
T cells in glucose-depleted conditions has been shown to inhibit signaling through
mTOR activation and selectively down-regulate gene to impair cell cycle

16

progression, cytokines production and cytotoxic ability of effector T cells (Cham and
Gajewski, 2005, Cham et al., 2008). It was also found to be true that mutation BRAF
V600E, which is commonly expressed in melanoma with constitutive activation of the
MEK-MAPK pathway, generate a tumor that has a strongly immunosuppressive
microenvironment. T cells isolated from BRAF V600E tumors had decreased CD40L
expression and IFN-γ production, which support the idea that tumor metabolism may
directly alter anti-tumor T cell immunity (Ho et al., 2014). All of these pieces of
evidences suggest that metabolic reprogramming is intimately tied with T cell
function and is therefore is central to effective immunity against tumors. The
outcome of an antitumor response may be swayed one way or the other by the
ability of T cells to cope with modulation in nutrient availability in the
microenvironment.

While it is relatively easy to envisage how T cells in a solid tumor could be at a
competitive disadvantage for nutrients, and that this would negatively affect their
function, this paradigm can additionally be extended to other setting that perhaps
less obvious. Gut environment is a special hub where groups of bacteria species,
termed “microbiota” reside and produce multiple metabolites that can interact with
host tissues and immune system thus can have profound effects on T cell
development and function (Nicholson et al., 2012, Mockler et al., 2014). For
example, the bacteria production of short-chain fatty acids such as butyrate within
the gut has been shown to alter the balance of Th17 and Treg cells as well as
altering T cell mTOR signaling (Berod et al., 2014). Acetate, another metabolites
fermented by intestinal microbiota has been determined to regulate the size and
function of colonic Treg pool thus promotes colonic homeostasis and health (Smith
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et al., 2013). Notably, when acetyl-CoA carboxylase, an important enzyme in fatty
acid synthesis is blocked either genetically or by the bacterial metabolites Soraphen
A, naïve T cells favor to polarize to Treg cell fate instead of Th17 cells. The
alternation in metabolic pathway that bias T cell differentiation away from Th17 cell
development has been implicated to contribute to Th17 mediated diseases including
multiple sclerosis or Crohn’s disease (Wilke et al., 2011). Given evidences above, it
is possible that other metabolites generated by commensal bacteria that modulate
cell metabolites and influence immune responses, possibly regulating autoimmune
susceptibility in human. All together, understanding how diverse cell populations or
organisms influence the tissue microenvironment, and how this environment dictates
metabolic pathway engagement by T cells, and thus differentiation and function is
essential for developing effective T cell-based immunotherapies.
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§ 1.5 Metabolites as signaling molecules connecting metabolism and gene
regulation

As described before, signaling transduction pathway, such as T cell activation signal
through its TCR can drive cellular metabolism above the capacity normally
maintained in the quiescent. This proliferation signal mediated metabolic
reprogramming required to match the biological need can not only influence
downstream signals of cell surface receptors through these metabolic pathways but
also serve as a feedback system to regulate metabolic flux through local nodes in
the network. Energetic intermediates and metabolites generated in this process
involved in bioenergetics and biosynthetic reaction that influence cell growth and
survival. Metabolites within cells can also act as signaling molecules that participate
in T cell signaling to shape T cell function and fate, and thus the availability of
particular metabolites can dramatically affect both cellular metabolism and cell
signaling.

One of the key metabolic intermediates acetyl-CoA is not only oxidized in TCA cycle
for energy generation and fatty acid synthesis, but also involved in the regulation of
gene transcription, transcription factor signaling, enzyme activity through protein
acetylation (Wellen and Thompson, 2012, Choudhary et al., 2014). In the nutrient
rich and normoxic conditions, the primary source of acetyl-CoA is glucose, which is
converted to pyruvate through glycolysis via PDH enzyme complex. As one of the
major carbon source, acetyl-CoA enters TCA cycle to generate reducing equivalents
(NADH, FADH) and to drive electron transport chain. Mitochondrial acetyl-CoA can
only pass across the mitochondrial membrane entering cytoplasm in form of citrate.
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In the cytoplasm, the enzyme ATP-citrate lyase converts citrate back into acetyl-CoA
to be used in fatty acid synthesis or protein acetylation. In contrast, under hypoxic
condition, reduced PDH activity limits OXPHAS in the mitochondrial, thus synthesize
less acetyl-CoA but more lactate through TCA cycle. Similarly, other substrates such
as glutamine, which is important in cells to converted to glutamate by glutaminase,
only make partial pass through TCA cycle and are exported from mitochondria as
malate. As a result, the level of acetyl-CoA derived from glucose and glutamine
drops, which may correlate to the levels of histone acetylation in an ACL-dependent
process (Wellen et al., 2009).

Other metabolic intermediates also act as signal transducers drive diverse
downstream biological processes. Take succinate for example, it is derived from
TCA cycle, which can induce IL-1β inflammatory signal in macrophages through HIF1α stabilization (Tannahill et al., 2013). The accumulation of fumarate, due to
fumarate hydratase deficiency, leads to several changes within cancer cells,
including to hypermethylation and HIF-1α stabilization (Sullivan et al., 2013).
Transport of amino acid is also required for T cell metabolic reprogramming.
Intracellular leucine level can influence mTOR activity via leucyl-rRNA synthetase
thus low concentration of leucine will impair mTOR function. Accordingly, it was
reported that expression of cytosolic branched-chain aminotransferase (BCATc) that
transaminates leucine, negatively regulation mTOR activity during T cell activation to
prevent overactivation (Ananieva et al., 2014).

One innovative way we consider the ability of metabolism within cells to influence
their biological function is to govern gene expression through posttranscriptional
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regulation network involving RNA, metabolites and metabolic enzymes. Many
enzymes involved in metabolic pathway, including glycolysis, PPP and fatty acid
metabolism, have been shown to bind RNA thus specifically regulate protein
translation in vitro and in culture cells (Hentze and Preiss, 2010). In addition, RNA
binding function of enzymes can be influenced by interaction with other metabolites
or cofactors, demonstrating how metabolic state of cells can link to gene regulation
through the control of RNA binding function of the enzyme. The well characterized
metabolic enzyme as an RNA binding protein is cytosolic aconitase, which is the key
regulator of cellular iron metabolism (Hentze and Argos, 1991, Rouault et al., 1991).
It was reported that cytosolic aconitase share the same polypeptide with RNA
binding protein IRP-1 which is available to insert or remove an iron sulfur cluster,
thus switching the protein’s function between RNA binding activity in low iron
condition as IRP-1 and metabolic enzyme activity in high iron environment
(Constable et al., 1992). This dual function of aconitase is essential in regulation
iron homeostasis.

Following the idea that bifunctional enzymes with the ability of RNA binding may
present a general mechanism of how metabolism and gene expression are
coordinated, our lab identify another glycolytic enzyme glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) function as a RNA binding protein, which can regulate
posttranscriptional production of IFN-γ in T cells by engaging or disengaging the
glycolysis pathway (Chang et al., 2013). Active T cells can dynamically switch
between OXPHOS or glycolysis for ATP generation. When T cells do not engage in
glycolysis pathway but using OXPHOS, GAPDH binds the 3’UTR of cytokine
mRNAs, including IFN-γ and IL-2 to prevent translation of these mRNAs. Thus
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although OXPHOS can support T cell survival or proliferation, only aerobic glycolysis
can facilitate their full effector function. This control mechanism allows T cell
uncouple its survival and proliferation from effector function, creating a checkpoint for
T cells to differentially govern cytokine production when is not desirable during
hemostasis. The activity of GAPDH is not only controlled by substrate availability but
is also heavily influenced by redox balance within the cells. For example, NAD+ is
required for GAPDH enzymatic function but it is also interferes with mRNA binding in
vitro (Nagy et al., 2000). NAD+/NADH redox balance, which may influence by other
metabolic enzymes including LDHA and PHGDH, could also affect posttranslational
modification of GPADH, altering its binding to mRNA, metabolites as well as
localization in the cell (Colell et al., 2007, Tristan et al., 2011). All in all, these
observations clearly demonstrate how cofactors and substrates generally considered
for their direct effects on metabolism may also coordinate metabolism with gene
regulation.
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§ 1.6 Targeting T cell metabolism as a effective adoptive immunotherapy

Researches in the last decade has accumulated a wealth of evidence demonstrating
how metabolic reprogramming intrinsically link to T cell biology, as well as how
metabolic alternation impacts T cell activation, differentiation and ultimately,
immunological consequence during infections and cancer. Emerging concepts about
targeting metabolic pathway for more effective adoptive immunotherapies to recue T
cell dysfunction in tumor microenvironment, as well as to prevent undesirable
pathogenic T cell response in settings of autoimmunity will be highlighted in this
chapter.

Substrate availability in the microenvironment has been shown as a major impact on
T cell function in vivo, and clearly the environmental impact on T cells also present in
vitro culture system. There has been a huge effort put into the development of
adoptive cellular immunotherapy for cancer and viral infection, whereby naturally
occurring or engineered T cell are stimulated and expanded in vitro before
transferring back to the patients (Maus et al., 2014).

The first use of chimeric

antigen receptor (CAR)-modified T cells was in HIV infection, which engineered with
receptors for HIV envelope protein fused to TCR downstream signaling molecule to
induce antigen-specific T cell response. In setting of solid tumors, immune-based
clinical interventions were proposed to convert TILs into effective cells, which
includes systemic administration of cytokines such as IL-2 and interferon, antibody
treatments aimed at modifying T cell activation and therapies targeting inhibitory
pathway by relieving checkpoint blockade. Specially, checkpoint blockade antibodies
against CTLA-4, PD-1/PDL-1, 4-1BB as well as CD40 has had remarkable result not
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only in advanced melanoma, but also lung caner that has been preciously been
described as “immunologically silent” with poor response (Hodi et al., 2010, Topalian
et al., 2012). The combination of two checkpoints in melanoma significantly improved
the response rate and time to tat over either therapy alone (Wolchok et al., 2013).
Direct isolation and ex vivo activation of TILs have also been tested in multiple earlyphase studies and result in durable responses in advanced melanoma (Rosenberg
et al., 2011). Although phenomenal success has been achieved using adoptive
cellular immunotherapy, many patients still failed to response following with poor
clinic outcomes. Given the substantial amount of evidences showing the intrinsic link
between T cell activation and metabolism, research directed at manipulating
metabolic pathway which can positively affect T cell function and longevity may
potentially enhance therapeutic efficacy and lead to better patient outcomes
(Sukumar et al., 2013).

Altering culture conditions for adoptive cellular immunotherapy in order to change the
metabolism is one way in which T cells could be restrained from terminal
differentiation while being optimized for persistence in vivo. For example, many
commonly culture media contains glucose concentration ranging from 10mM to
25mM, which is substantially higher than physiological glucose level in the normal
blood stream. High glucose in the culturing media may potentially induce
hyperglycemia in proliferating T cells that become overly dependent on glycolysis
through metabolic reprogramming (Glick et al., 2014). It may risk the effect of T cells
that are transferred back into patients when exposing to low physiological glucose
level again because the augmentation of glycolysis in CD8+ T cell limits its long-term
survival (Sukumar et al., 2013). It has also ben shown that increased glycolysis
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positively correlates to cell size, which is negatively impact mitochondrial gene
expression as well as cell survival in vivo (Manjunath et al., 2001). Likewise,
constitutive activation of Akt can enhance cellular glycolysis and increase surface
expression of glucose transporters, which result in enlarged cell size. Conversely,
limiting T cell glycolysis using low dose 2-deoxyglucose (2-DG) by inhibiting
hexokinase in vitro can reduce cell size and increase longevity without impairing
proliferation capacity. All together, these data indicate that appropriate culture
conditions can improve adoptive T cell transfer therapy through direct modulation of
metabolism. Moreover, biological parameters such as cell size or glycolytic rate may
be used as predictors of in vivo T cells fitness and function, which are activated in
vitro.

The replicative capacity and long-term survival of adoptive transfer cells may also be
promoted by enhancing OXPHOS or mitochondrial biogenesis instead of limiting
overly glycolysis. There is the evidence showing that by inhibiting Akt signaling
pathway, in vitro expanded TILs increase their rates of OXPHOS and FAO, which
benefit their in vivo survival and anti-tumor function (Crompton et al., 2015). As
mentioned before, the administration of cytokines that signal via receptors containing
common γ chain including IL-15 or IL-7, allows the substantial cell survival,
population expansion and effector function. These in vivo beneficial effect induced
by these cytokines has at least partially link to metabolic reprogramming. IL-15
reduces glycolysis while enhance OXPHOS and SRC in activated CD8+ T cells along
with increased mitochondrial mass. Observations from our lab indicate that, in
addition to accumulated mitochondrial mass, the morphology of mitochondrial in
memory T cells dynamically changed and appeared to be networked, which is
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distinct to their counterpart effector T cells with punctate mitochondrial (Buck et al.,
2016). These fission and fusion events that constantly happened in the mitochondria
in T cells regulate metabolism, longevity as well as cell fitness (Chan, 2012,
Westermann, 2012, Youle and van der Bliek, 2012). As a result, pharmacologically
targeting mitochondria to enhance their function may present an effective way for the
improvement of adoptive transferred T cell therapy. For example, Szeto-Schiller (SS)
peptides, which target cardiolipin within mitochondria in order to optimize the
efficiency of electron transport chain, has been tested in Phase II clinical trials
potentially as the treatment for ischemic reperfusion injury (Chakrabarti et al., 2013).

Tumor microenvironment is complicated network that not only contains malignant
cells but also includes stromal and epithelial cells, as well as a group of tumor
associated immune cells. The presence of various cell types may result in an
inhospitable nutrient environment for effector T cells to exert their optimal functions.
For instance, the depletion of amino acid such as arginine and tryptophan
(Uyttenhove et al., 2003, Rodriguez et al., 2004), the competition consumption of
other nutrients including glucose and lipids (Wang et al., 2014, Chang et al., 2015),
as well as the production of metabolites such as lactate in the tumor
microenvironment could all lead to alteration of T cell metabolism thus impact their
anti-tumor functions (Fischer et al., 2007). Likewise, a recent study explained that
tumor-derived lactate can drive expression of arginase I in tumor-associated
macrophages, result in polarization into M2 phenotype, which presents as an
immunosuppressor inhibiting T cell function and promoting tumor progression.
Another example of metabolic and environmental influences on T cell function in vivo
is the competition model of nutrient in the tumor microenvironment, in which effector
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T cells compete with tumor cells for available glucose, and this tumor cells imposed
nutrient restriction dampens T cell effector cytokine production, leading to cancer
progression (Chang et al., 2015). It seems like overall suppressive nature of the
tumor microenvironment contributes to impaired T anti-tumor immunity.

There have been a lot of efforts put on modifying cancer metabolism with the hope of
improving the efficacy of anti-tumor therapies. The problem of this strategy is that
activated T cells and cancer cells often share similar metabolic traits, thus targeting
tumor cell metabolism has the potential to also negatively impact infiltrating effector
T cells. One way to avoid this problem is to focus on developing small molecule
compounds

that

target

metabolic

pathway

in

a

tumor-specific

manner.

Aforementioned BRAF V600E described before is a clear tumor-specific therapeutic
target in melanoma without detrimental effect on TILs. Another experimental AGI
compounds have been developed to specifically inhibit the mutation forms of
isocitrate dehydrogenase (IDH) enzymes and thus have shown anti-tumor potential
against glioma and leukemia in vitro (Rohle et al., 2013, Wang et al., 2013). The
combination small molecule compounds targeting tumor metabolism with adoptive T
cell transferring immunotherapy theoretically presents a way to create a tumor
microenvironment that is metabolic favorable for transferred T cells to exert their
optimal anti-tumor functions.

There is substantial interest in optimizing T cell function against viral infections and
cancer through metabolic regulation. On the other hand, undesirable T cell activation
in the setting of graph versus host disease (GvHD) as well as autoimmune disorder
may also be prevented via modulation of metabolic pathway. For example,
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alloreative T cells from GvHD appear to rely on OXPHOS, thus targeting TCA cycle
reaction or mitochondria ATP production could specifically limit the activation of
these cells. Following this idea, metformin, which is the inhibitor of complex I of the
electron transport chain, could potential has the therapeutic effect on GvHD,
particularly in the setting that alloreactive T cells exhibit hyperpolarized mitochondria.
Mitochondria function or ATP generation can also be inhibited by limiting the activity
of carnitine palmitoyl transferase (CPT)-1a, which blocks oxidation of long-chain fatty
acids in the mitochondria. Pharmacological agents such as etomoxir or perhexiline,
could be used to selectively target GvHD T cells with higher rates of FAO compared
to their counterparts (Byersdorfer et al., 2013).

To

facilitate

targeting

specific

cell

population

in

the

microenvironment,

nanotechnology is being innovated and used for the delivery of small molecule
compounds for therapeutic purpose. Because this method allows the control and
sustained release of a compound in a cell specific manner, it could be extremely
useful tool for delivering metabolism-modifying compounds of T cells. One type of
this drug encapsulation system is biodegradable poly lactide-co-glyceride (PLGA)
nanoparticles, which allows controlled released of drug from days to months
(Mundargi et al., 2008). With conjugated antibodies against T cell surface marker,
PLGA nanoparticles can directly target T cell population and block their metabolic
pathway by delivering glycolysis inhibitor 2-DG or dichloroacetate (Gerriets et al.,
2015), L-type amino acid transport inhibitor JPH203 (Gerriets et al., 2015), or lactate
transporter inhibitors like AR-C141990 (Pahlman et al., 2013) as a way to limit
hyperactive T cell inflammatory responses in autoimmune disorder. This delivery
system has proven to be effective for leukemia inhibitory factor, which is used to
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oppose Th17 cell differentiation and enhance Treg cell development in a mouse
model of allograph rejection (Park et al., 2011).

Last but not least, the idea of bi-specific antibodies with two independently targeted
antigen binding fragmentation (Fab) regions can simultaneously bind to two type of
cells together. These proteins have been primarily explored as cancer therapies,
where the bi-specific antibody is used to bring tumor cells and cytotoxic T cells
closed enough for antigen-specific killing. This technology could be extended to
apply in modifying T cell metabolism thus modulate their functions. The use of a
strong-binding antibody against T cell surface marker could be conjunction with a
low-affinity antagonistic antibody against substrate transporter to inhibit T cell
activation or delivery protein conjugated with carbohydrates such as glucose to
enhance T cell function. The advantage of this approach would be the hierarchy of
binding affinity could ensure the delivery of desired molecules is only targeted cells
that express specific markers.
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§ 1.7 Emerging topics and concluding remarks

Immune cells undergo dynamic changes during the course of immune response. In
the past few years, generous amount of emerging findings indicate the
interconnection between cell signaling and biomedical pathways. All parameters of
these fields are directly intertwined, comprising an integrated network from gene
expression to metabolite production. Studies on T cell provide a unique opportunity
to understand how metabolism supports normal T cell biology including survival and
proliferation as well as how metabolic alternation drive T cell differentiation and fate.
Characterizing how metabolic pathway regulated in T cells, how perturbations in the
microenvironment influence T cell responses, and how metabolic response are
modulated in vivo in the context of systemic stress such as infection or cancer and
eventually contribute to the outcome of T cell mediated immune response are still
active challenging topics in this field. Applications of pharmacologic reagents as well
as advanced nanotechnology that interfere with metabolic pathway with the
appreciation for the role of metabolism in dictating immune cell function holds
promise for revolutionary new treatments and therapies in the near future.
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CHAPTER 2

METABOLIC COMPETITION IN THE TUMOR MICROENVIRONMENT
IS A DRIVER OF CANCER PROGRESSION
(Published in the September 10th, 2015 issue of Cell)
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§ 2.1 Introduction

Establishing why some cancers progress while others do not is a longstanding
challenge in immunology. The immune system is often capable of distinguishing
nascent tumor cells, and the recognition and destruction of strongly immunogenic
tumors by T cells is a critical part of the anti-tumor immune response. However,
during this process, cancer cells that express weakly immunogenic antigens will
evade killing and thus be selected for outgrowth. This is thought to be a primary
mechanism of tumor progression (Vesely and Schreiber, 2013). Another mechanism
by which tumors are known to escape anti- tumor immunity is through T cell
dysfunction, or hyporesponsiveness. Hyporesponsive states such as anergy,
exhaustion, and senescence, have all been described in T cells from cancer patients
(Wherry, 2011, Crespo et al., 2013) – and chronic TCR stimulation, lack of proper
costimulation, and active suppression by other cell types in the tumor
microenvironment have all been implicated in T cell dysfunction. However, whether
other mechanisms exist, or precisely how T cell hyporesponsiveness in tumors is
established, remains to be fully defined.
Nutrient competition between cells can influence cell growth, survival, and function,
and a fierce competition likely exists between cells in the tumor microenvironment,
as the demand for resources in this niche is high. Metabolic interplay between tumor
cells and immune cells has been demonstrated. For example, tumor cells can
express indoleamine 2,3-dioxygenase (IDO), an enzyme that depletes tryptophan
from the microenvironment and thus inhibits T cell proliferation (Munn et al., 1999,
Munn and Mellor, 2013). Tumor-derived lactate can also suppress T cell function
directly by blocking lactate export from T cells (Fischer et al., 2007), which disrupts

32

their ability to maintain aerobic glycolysis. We previously published that, via a
posttranscriptional mechanism, the engagement of aerobic glycolysis is specifically
required for effector function in T cells, but not necessarily for T cell activation,
proliferation, or survival (Chang et al., 2013). We also showed that in culture, tumor
cells can outcompete T cells for glucose, and this lack of available glucose directly
impedes the production of cytokine that can be critical for tumor clearance. Since
many tumors have high rates of aerobic glycolysis (Warburg, 1956, Gatenby and
Gillies, 2004), we hypothesized that tumor-infiltrating CD8+ T lymphocytes (TILs)
could experience a loss of function during cancer due to altered metabolism resulting
from tumor-imposed glucose restriction, and this subsequently could lead to defects
in cytokine production and tumor clearance. Therefore we sought to formally
establish whether glucose competition in the tumor microenvironment, in its own
right, determines cancer progression by regulating the ‘nutrient-fed’ state of tumorinfiltrating T cells, and thus their functionality.
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§ 2.2 Tumor glucose-restrict T cells, altering their metabolism and function

To investigate how glucose competition between tumors and T cells affects T cell
function, we used an established mouse sarcoma model of regressing and
progressing tumors (Matsushita et al., 2012, Gubin et al., 2014). D42m1-T2 (referred
to here as ‘R’ tumor) is a regressor clone of the d42m1 sarcoma that expresses the
major tumor- specific rejection antigen mutant spectrin-β2. After transplantation into
mice, this tumor is rejected at ~day 12 in a manner that depends upon IFN-γ
production from TILs (Matsushita et al., 2012). D42m1-T3 (referred to here as ‘P’
tumor) is a progressor clone of d42m1 that lacks this rejection antigen and grows
progressively after transplantation into mice (Figure 1A). Consistent with our
published results using other tumor cell lines (Chang et al., 2013), we co-cultured R
and P tumors with C3 T cells, a cytotoxic T lymphocyte (CTL) clone that recognizes
mutant spectrin-β2 (Matsushita et al., 2012), and found less glucose in the media
when T cells were cultured overnight with tumor cells than when the same total
number of T cells were cultured alone (Figure 1B), indicating that these tumors
consume more glucose than T cells on a per cell basis. However, we also found that
there was less glucose remaining in the media when T cells were co-cultured with P
tumor cells, than with R tumor cells (Figure 1B). While the T cells co-cultured with R
tumor cells produced less IFN-γ than T cells cultured alone, we found that production
of this cytokine was dampened even further in T cells co-cultured with the P tumor
cells (Figure 1C). We observed similar results in IFN-γ production when the tumors
were co-cultured with polyclonal T cells rather than the CTL line (data not shown).
Importantly, adding glucose during the restimulation enhanced T cell IFN-γ
production (Figure 1C), indicating that glucose availability and utilization, and thus
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competition for this sugar, rather than the presence of other metabolites such as
lactate, had a direct role in regulating T cell effector function in these co-cultures. We
further confirmed that the extracellular acidification rate (ECAR), which is an
indicator of aerobic glycolysis, the process where glucose is converted to lactate
even in the presence of sufficient oxygen to support glucose catabolism via the TCA
cycle and oxidative phosphorylation (Nicholls et al., 2010), was higher in the P tumor
than in the R tumor (Figure 1D, left panel), supporting the data showing that the P
tumor consumes more glucose than the R tumor (Figure 1B). Although the ECAR of
these R and P tumors differed, their rates of proliferation in vitro were similar (Figure
1D, right panel), demonstrating that glycolysis is not necessarily directly coupled to
the proliferation of these tumor cells. These results suggested that a defect in T cell
effector function in the P tumor microenvironment could be due to a metabolic deficit
imposed by glucose restriction.
Although the R and P tumors differ in their antigenicity, it has been shown that
tumor-specific T cells infiltrate both tumors (Matsushita et al., 2012, Gubin et al.,
2014). We transplanted either R or P tumor cells into naïve 129S6 mice and
analyzed activation markers on TILs ~day 12 after transplantation (Figure 1E). We
found that TILs in the R and P tumors had a CD44hiCD62Llo effector T cell
phenotype and expressed T-bet (Figure 1F, top), suggesting that the TILs present in
both tumors were activated and transcriptionally competent to produce IFN-γ (Parish
and Kaech, 2009, Anichini et al., 2010). However, as has been previously shown
(Gubin et al., 2014), TILs in the P tumors were PD-1hi, consistent with their
hyporesponsive phenotype (Ahmadzadeh et al., 2009, Baitsch et al., 2011). Grossly,
the infiltrates of immune cells were similar in R and P tumor on day 12, although the
relative frequency of T regulatory (Treg) cells and the balance of M1- versus M2-
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polarized macrophages differed (Figure 2). Together these results suggested that
activated TILs infiltrate both P and R tumors (Matsushita et al., 2012, Gubin et al.,
2014), but that TILs in the P tumor develop a state of hyporesponsiveness. As we
have shown previously that nutrient restriction can lead to hyporesponsiveness in T
cells in vitro (Chang et al., 2013), we wondered whether the high glycolytic rate of P
tumors effectively limits glucose availability within the tumor microenvironment and if
this contributes to the hyporesponsive state of TILs in this niche.
Mechanistic target of rapamycin (mTOR) is an environmental sensor, and mTOR
pathway signals decrease when nutrient availability is low (Kim et al., 2002, Gatenby
and Gillies, 2004). Therefore, we reasoned that mTOR pathway activity in TILs
would directly reflect the nutrient status of these cells within the tumor
microenvironment. We measured mTOR target activation in TILs from R and P
tumors directly ex vivo and found that phosphorylation of 4E-BP1 and S6 kinase was
decreased in P tumor-TILs when compared to the phosphorylation of these proteins
in R tumor-TILs (Figure 1F, bottom). These data support the view that P tumor cells,
which consumed more glucose (Figure 1B) and displayed a higher ECAR (Figure
1D, left), and thus had a higher glycolytic rate, imposed a more severe glucose
restriction on TILs than did R tumor cells.
Inhibitory signals from molecules such as PD-1, or from Treg cells, also dampen T
cell responses in tumors (Keir et al., 2008, Francisco et al., 2010, Simpson et al.,
2013) and we speculated these signals might further inhibit the ability of TILs to
compete for glucose in a tumor. However, we wanted to test the idea that metabolic
competition between cells in a microenvironment is a fundamental force that drives
immune cell phenotypes. Therefore, we considered that nutrient competition by P
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tumor cells alters the metabolism of TILs within the same tumor niche, and in turn
dampens their effector function. To begin to investigate the metabolic landscape in
the tumor microenvironment, we assayed the metabolism of TILs from excised R and
P tumors on day 12 post-transplantation. We found that ECAR of TILs from P tumors
was lower than that of TILs from R tumors (Figure 1G, left), indicating less aerobic
glycolysis in these cells. Notably, unlike TILs from R tumors, TILs from P tumors
were impaired in their capacity to augment glycolysis when mitochondrial respiration
was blocked by the ATP synthase inhibitor oligomycin (Figure 1H). As we found to
be the case for P tumor cells in vitro, ex vivo P tumor cells also exhibited higher
ECAR when compared to R tumor cells. This elevated ECAR was inversely
proportional to the metabolism of the TILs that were isolated from that tumor (Figure
1G, right), indicating a metabolic interplay between tumors and their TILs. After
restimulation, TILs from the P tumor produced significantly less IFN-γ than TILs from
the R tumor (Figure 1I), directly illustrating a relative lack of functionality in the P
tumor metabolically-restricted TILs. Importantly, the glucose concentration in the
extracellular milieu of P tumors was significantly lower than in R tumors (Figure 1J).
These data show that elevated ECAR of P tumor cells directly correlates with lower
glucose availability in their tumor microenvironment, and are consistent with the idea
that high glucose consumption by tumors cells can cause glucose depletion within
the tumor niche. To directly address whether TILs in P tumors are glucose-restricted,
we intravenously injected the fluorescent glucose analog 2-NBDG and tracked its
uptake by TILs in P vs. R tumors. We found that TILs in P tumors acquired less 2NBDG than those in R tumors (Figure 1K), which is consistent with their reduced
ECAR (Figure 1G, left). Taken together, these results suggest that TILs are nutrientrestricted in the P tumor microenvironment, and that this accounts for their impaired
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glycolytic capacity and effector function in this niche.

38

Figure 1. Tumor mediated glucose restriction alters the metabolism of T cells
and dampens their ability to produce cytokine
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(A) 1x106 MCA-induced sarcoma d42m1 derived regressor (R) or progressor (P)
tumor cells were injected s.c. into 129S6 mice (n=5) and tumor growth was
monitored. Tumor size is shown as the average of two perpendicular diameters ±
SEM from 10 mice of 2 independent experiments. (B) C3 T cells were cultured alone,
or with a 1:5 ratio of P or R tumor cells for 24h. Cells were then restimulated with
PMA/ionomycin for 5h and IFN-γ production was measured. At the time of
restimulation, either no additional glucose or 20 mM glucose (Glc) was added to the
media. The percentage of IFN-γ+CD8+ cells is depicted on the top right and the mean
fluorescence intensity (MFI) of CD8+ cells is shown vertically. The results are
representative of ≥ 2 independent experiments. (C) Glucose concentrations in the
media of the above co-culture were measured before stimulation. Data represent at
least 2 independent experiments and are shown as mean ± SEM, **p=0.0087 and
***p=0.0011. (D) ECAR and proliferation of R or P tumor cells. R or P tumor cells
were labeled with CellTrace Violet (CTV) and cultured for 3 days. CTV dilution was
measured at days 0 and 3. Data represent ≥3 independent experiments, ***p=0.001.
(E) R or P tumors were injected s.c. into 129S6 mice and TILs were isolated from
bulk tumors ~12 days post- transplantation. (F) CD44, CD62L, PD-1, T-bet,
phosphorylated 4E-BP1 (p4E-BP1), and phosphorylated S6K (pS6K) expression
were measured in TILs by flow cytometry. Data are representative of ≥3 independent
experiments. (G) ECAR and OCR/ECAR ratios of ex vivo tumor cells and their TILs
were analyzed. Data are shown as mean ± SEM from 3 independent experiments.
**p=0.003, ***p=0.001. (H) Glycolytic capacity of TILs was measured after exposure
to the mitochondrial ATP synthase inhibitor oligomycin. Bar graph is shown as mean
± SEM and is representative of 2 independent experiments. (I) IFN-γ production in
TILs was measured 5h after PMA/ionomycin restimulation. Contour plots (above)
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and MFI of IFN-γ producing cells are shown (below). Results represent data from ≥3
independent experiments. (J) Glucose concentration in the extracellular milieu of ex
vivo tumors, ***p=0.0005. Data shown are the average of 5 individual mice. (K) 100
µg 2-NBDG was injected i.v. into a tumor-bearing mice and tumors were harvested
15 min later. The representative histogram (above) depicts 2-NBDG uptake in TILs.
The bar chart (below) shows mean MFI ± SEM from 3 individual mice. **p=0.0147.
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Figure 2. In vitro glucose competition between tumors and T cells, and
composition of immune cell infiltrates in R and P tumors in vivo
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(A) R tumor cells were pre-treated with 100 nM rapamycin (Rapa) or 4-hydroxytamoxifen (4-HT) for 2 days and ECAR of cells were measured. Data are from one
experiment. (B) Activated OT-I CD8+ T cells were cultured with a 1:3 ratio of
rapamycin- pretreated R tumor cells overnight. IFN-γ production was measured after
PMA/ionomycin stimulation for 5h. (C) 4-HT-pretreated R tumor cells were
cocultured with activated OT-I CD8+ T cells at a 3:1 ratio overnight. Cells were then
restimulated with PMA/ionomycin and IFN-γ production was measured. At the time of
restimulation, either no additional Glc or indicated Glc concentrations were added to
the media. The percentage of IFN-γ+CD8+ cells is depicted on the top left, and IFN-γ
MFI of CD8+ cells is shown vertically. Data (B and C) are representative of 3
independent experiments (D) The composition of infiltrating CD45+ cells in R and P
tumors was assessed at 9-13 days after transplantation. Frequencies of CD3+CD8+
and CD4+ T cells, F4/80+CD64+ macrophages, CD19+ B cells, and the rest of CD45+
cells (Others) are shown. Bar chart is presented as percentage of mean frequency ±
SEM from at least 4 independent experiments. (E) Infiltrating Treg cells in R and P
tumors were determined as FoxP3+CD4+ T cells. Relative composition of Treg cells
was calculated by normalizing the frequencies of the cells to those in the R tumor.
Data are shown as mean ± SEM from 3 independent experiments. (F) M1 (iNOS+
cells) and M2 (RELMα+ cells) macrophages in R and P tumors were assessed at 12
days after transplantation. Bar chart is presented as M1 verse M2 ratio ± SEM from 2
independent experiments.
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§ 2.3 Tumor-imposed nutrient restrictions lead to T cell hyporesponsiveness
even when tumors are highly antigenic

Antigen-specific T cell responses are critical for mediating tumor clearance (Baitsch
et al., 2011, Matsushita et al., 2012) and antigenic mutant spectrin-β2 expressed by
R (but not P-) tumors has been shown to be an important target for tumor rejection
(Matsushita et al., 2012). Given that the antigenicity of R and P tumors differs, we
designed a series of experiments that would address how nutrient competition alone
could affect the activity of T cells in tumors. To begin to explore this question we
used an EL4 lymphoma that expresses Ova peptide (EL4-Ova), allowing us to target
the cancer with Ova- specific (OT-I) CD8+ T cells, and thus determine the impact of
nutrient limitation in T cells with defined tumor antigen specificity. We used a model
in which we could enhance nutrient restriction simply by increasing tumor cell
number, and injected either 1x106 or 40x106 EL4-Ova cells intraperitoneally, and
then intravenously transferred 2x104 naïve OT-I CD8+ T cells into these mice (Figure
3A). Seven days later we assessed T cell responses in the peritoneal cavity and
found that, while OT-I T cells infiltrated the peritoneal cavities of mice carrying high
or low peritoneal tumor burdens, mTOR activity in OT-I T cells was greatly
dampened in mice injected with 40x106 EL4-Ova tumor cells compared to those
mice which had received 1x106 EL4-Ova cells (Figure 3B). Moreover, the OT-I T
cells in mice inoculated with 40x106 EL4-Ova cells exhibited reduced IFN-γ
production after restimulation compared to OT-I T cells in mice which had received
1x106 EL4-Ova cells, and this reduced responsiveness in the context of the larger
tumor burden was also apparent in endogenous CD8+ and CD4+ T cells that had
entered the peritoneal cavity as part of the anti-tumor response in these mice

44

(Figure 3C). Furthermore, in mice that had received OT-I cells and 40x106 EL4-Ova
cells seven days earlier, we twice injected a bolus of glucose, or PBS, along with
Brefeldin A, 2.5 and 5 hours prior to assessing the IFN-γ production of OT-I cells in
the peritoneum. We injected BFA into the mouse so that we could capture IFN-γ
production, as it is in situ, without restimulation in high glucose in vitro. We found that
the T cells in the mice that had received injections of a high concentration of glucose
produce more IFN-γ (Figure 3D). Taken together, these data show that the effector
function of T cells, even antigen- specific ones (i.e. Ova-specific), can be affected by
an increased number of tumor cells, or glucose concentrations in vivo, suggesting
that tumor-imposed nutrient-restriction of T cells can be a general mechanism for
hyporesponsiveness.
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Figure 3. In vivo competition for glucose modulates cytokine production in
antigen-specific T cells
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(A) 1x106 or 40x106 EL4-Ova lymphoma cells were injected i.p. into C57BL/6 mice
that received 2x104 naïve OT-I Thy1.1+ CD8+ T cells by i.v. injection. Cells from the
peritoneal exudate were assessed 7 days post-inoculation. (B) Phosphorylation of
4E-BP1 (p4E-BP1), S6K (pS6K), and S6 (pS6) of OT-I cells was assessed by flow
cytometry and relative MFI from mice transplanted with either 1x106 EL4-Ova cells or
40x106 EL4-Ova cells (40) was normalized to the MFI of T cells from mice injected
with 1x106 EL4-Ova cells (1). Bar graphs are shown as mean ± SEM and are from 4
independent experiments. **p=0.0085, ***p=0.001. (C) IFN-γ production by OT-I
CD8+ donor T cells as well as CD8+ and CD4+ host T cells was measured after 5h
PMA/ionomycin restimulation. Dot plots showing IFN-γ production are representative
of 2 independent experiments. Vertical number is the MFI of IFN-γ+ cells. (D) In vivo
IFN-γ production by OT-I CD8+ donor T cells was measured. Mice were injected i.p.
with EL4- Ova cells and i.v. with congenic naïve OT-I T cells. On day 7 posttransplatation, mice were injected i.p. with Brefeldin A along with either PBS or
glucose, and then again 2.5 hours later. Cells in the peritoneal cavity were harvested
5 hours after the first injection and analyzed by flow cytometry. Dot plots showing
MFI of IFN-γ+ cells relative to the mice treated with PBS. Each dot represents an
individual mouse and horizontal bars indicate mean ± SEM combined from 2
independent experiments. * p=0.0142.
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§ 2.4 Nutrient competition between tumors and T cells can regulate cancer
progression

It is important to note that in the experiments depicted in Figure

3,

hyporesponsiveness developed in the face of increased antigen concentration. This
differs from published data showing that increases in cell-free antigen concentrations
promoted T cell responses until an upper limit of activation is reached, at which point
IFN-γ production plateaus (Constant et al., 1995). Thus, we reasoned that when
antigen is available and not limiting, tumors may assume a critical role in inhibiting
immunity through the more rapid consumption of available nutrients within the tumor
mass niche, leaving TILs at a metabolic disadvantage. To directly address whether
nutrient competition alone, outside of other extrinsic factors, could determine cancer
progression, we aimed to alter tumor cell metabolism, and then assess progression
and rejection of the altered tumors. By altering tumor cell metabolism directly, we
would be able to make comparisons between different groups using the same tumor
(rather than comparing different tumors derived from the same parental tumor, as is
the case when P and R tumors are compared). Making comparisons within one
tumor line would also remove the confounding factor of differing antigenicity, as the
same rejection antigens would be expressed. Furthermore, by only altering tumor
cell metabolism, we would be able to administer equivalent numbers of tumor cells
into mice, keeping tumor and antigen burden the same at the time of transplant, as
opposed to using a larger tumor burden to facilitate nutrient competition, as was the
case in the experiments depicted in Figure 3. To accomplish this we took advantage
of a recent study that showed that tumor cells cultured for extended periods of time
in low glucose adapt by increasing mitochondrial respiration (Birsoy et al., 2014),
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demonstrating that modulating nutrient availability enforces changes in tumor cell
metabolism. We cultured R tumor cells in high glucose (50 mM) and low serum (1%
FCS) over a number of weeks to select R tumor cells with increased glycolytic
capacity. During this same time period we cultured the original R tumor in control
media (11 mM glucose, 10% FCS). When returned to the control media, the resulting
R-1% tumor displayed enhanced ECAR and glucose uptake when compared to the
original R tumor, although not to the level of that observed in P tumor cells (Figure
4A, left). We transplanted R-1% tumors into mice and found that 10 out of 14
recipients developed either fully progressing tumors, or exhibited delayed tumor
regression (Figure 4B and 5A). At day 20, all 13 of the original R tumors had
regressed, while only 4 out of 14 R-1% tumors had fully regressed (Figure 4B and
5A). Critically, all of the R-1% tumors that progressed still expressed the major
rejection antigen mutant spectrin-β2 (Figure 4C and 5B), indicating that the gain of
the ‘progressor’ phenotype in R-1% tumors was not due to the loss of dominant
epitopes recognized by potentially protective T cells. Furthermore, we found that R
and R-1% tumor cells grow at the same rate in vitro (Figure 5C), as well as in RAG-/mice, which lack B and T cells (Figure 4D). These data demonstrate that the reason
for tumor progression in the immune competent mice was not due to acquired
differences in inherent rates of proliferation between the R and R-1% tumors, and
that the adaptive immune system mediates rejection of the R tumors in this setting.
We reasoned that the R-1% tumor behaved as a progressor tumor due to its
enhanced glucose uptake (Figure 4A, right). Therefore, we predicted that if this
were the case, then genetically manipulating the glycolysis pathway directly should
also turn the R tumor into a progressor tumor. To this end we performed a genetic
gain-of-function experiment and transduced R tumors with a retrovirus expressing c-
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Myc, a transcription factor that drives the glycolytic program (Gordan et al., 2007).
We found that c-Myc expressing R tumors cells (R-cMyc) displayed enhanced ECAR
in vitro (Figure 4E), when compared to R tumors expressing the empty control
vector (R-EV Ctrl), which was consistent with their increased glycolysis. Importantly,
we also observed that the R-EV Ctrl tumors displayed higher ECAR than nontransduced R tumor cells. These data suggested that while the enhanced glycolysis
of c-Myc expressing tumors should confer a strong progressor phenotype when
compared to non-transduced R tumors and R-EV Ctrl tumors, the R-EV Ctrl tumors
might also conceivably exhibit some progression compared to non-transduced R
tumors, due to their enhanced rate of glycolysis. We transplanted R-cMyc tumors
into mice and found that 22 out of 30 recipients (73%) had tumors equal to or larger
than 5 mm at day 21, while only 5 out of 41 mice (12%) with R- EV Ctrl tumors had
tumors larger than this size (Figure 4F and 5D). We reasoned that the elevated
ECAR in R-EV Ctrl tumors compared to non-transduced R tumors caused
progression or delayed regression in a few of the mice, when compared to nontransduced R tumors, which normally fully regress by day 21 (Figure 1A, 4B).
Therefore we compared between groups based on tumor size at day 21. Importantly,
c-Myc expressing R tumors maintained expression of the major rejection antigen
mutant spectrin-β2 (Figure 4G and Figure 5B). These data show that in spite of
expressing a major rejection antigen, c-Myc expressing tumors became more
glycolytic and gained a strong ‘progressor’ phenotype. Since c-Myc is an upstream
regulator of the glycolysis pathway, it is possible that this transcription factor may
drive other diverse programs beyond glycolysis in transduced tumor cells. To more
directly test the role of tumor cell glycolysis in the progression of antigenic tumors,
we transduced R tumors with a retrovirus expressing pyruvate dehydrogenase
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kinase 1 (PDK1), an enzyme that sits at a key bifurcation point between glycolytic
and oxidative metabolism (Gerriets et al., 2015). We also transduced T tumor cells
with the glucose transporter Glut1, and hexokinase II (HK2), the first enzyme in the
glycolysis pathway. We found that PDK1-, Glut1-, and HK2-expressing R tumors (RPDK1, R-Glut1, and R-HK2) displayed higher ECAR when compared to control
transduced cells, consistent with enhanced glycolysis (Figure 4E). We transplanted
these tumors into mice and found that 16 out of 25 of R-PDK1 transduced tumors
(64%), 6 out of 15 of R-Glut1 transduced tumors (40%), and 10 out of 15 of R-HK2
transduced tumors (67%) progressed, compared to only 5 out of 41 of the R-EV Ctrl
transduced tumors (12%) (Figure 4F and 5D). Importantly, the R-PDK1, R-Glut1,
and R-HK2 tumors continued to express the major rejection antigen mutant spectrinβ2 (Figure 4G and 5B). In addition, activated C3 T cells could still efficiently kill the
R-1% and the transduced R tumors when in nutrient rich conditions in vitro,
indicating that all of these tumors maintain expression of the target antigen mutant
spectrin-β2 (Figure 5E, F). Moreover, the transduced tumors cultured in vitro
(Figure 5G), or in RAG-/- mice, all grew at fairly similar rates (Figure 5H), indicating
that the difference in progression between the tumors transduced with glycolysis
genes and those transduced with EV Ctrl was not solely due to substantial inherent
differences in growth rates. We also injected 2-NBDG into mice bearing transduced
tumors and assessed its uptake in tumors and TILs. We found that all of the TILs in
transduced tumors acquired less glucose than TILs in tumors expressing the EV-Ctrl
(Figure 4H). Finally, we co-cultured transduced tumors with activated OT-I cells. We
found that the tumors transduced with glycolysis genes dampened IFN-γ production
in OT-I T cells more than the EV Ctrl transduced tumors, and that the addition of
glucose to the culture substantially increased IFN-γ production in the T cells (Figure
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5I). Taken together, these results demonstrate that tumor cell metabolism, which
itself drives a competition for nutrients, can determine cancer progression, even in
the presence of a major tumor rejection antigen recognized by the immune system.
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Figure 4. Enhancing glycolytic metabolism in antigenic tumors that are
normally rejected promotes tumor progression
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(A) R tumors were cultured either in complete media (11 mM glucose and 10% FCS:
R) or in high glucose and low FCS media (50 mM and 1% FCS: R-1%) over 3 weeks
and ECAR of the cells was measured (left). Tumor cells were cultured in 5 µg/ml 2NBDG at room temperature for 15 min and 2-NBDG uptake was measured by flow
cytometry (right). Data are the average of 3 independent experiments, with R and P
group values also used in Figure 5B. 2-NBDG MFI is normalized to the MFI values of
the R tumor. ECAR data are representative of 3 independent experiments,
***p=0.001. (B) 129S6 mice were injected s.c. with 1x106 R or R-1% tumor cells and
tumor growth was monitored. Tumor size is shown as an average of two
perpendicular diameters ± SEM. (C) cDNA was made from ex vivo isolated
progressing R-1% tumors and from cultured R and P tumors cells and amplified by
PCR for spectrin-β2. The PCR product was then digested with the restriction enzyme
Pst1 and analyzed by electrophoresis. Data presented are from 3 individual ex vivo
R-1% tumors. (D) 1x106 R or R-1% tumor cells were injected s.c. into Rag-/- 129S6
mice and tumor growth was monitored. Data (B and D) are from 2 independent
experiments. (E) R tumor cells (R-No Tdx) were transduced with either an empty
retroviral vector (R-EV Ctrl) or vectors expressing c-Myc (R-cMyc), PDK1 (R-PDK1),
Glut1 (R-Glut1), or HK2 (R-HK2). ECAR of indicated cells were measured. Data are
from at least 4 independent experiments. **p=0.0012 for R-EV Ctrl vs R-cMyc,
p=0.0091 for R-EV Ctrl vs R-PDK1, p=0.0026 for R-EV Ctrl vs R-Glut1, and
p=0.0196 for R-EV Ctrl vs R-HK2; ***p=0.001 for R-No Tdx vs R-EV Ctrl. (F) 2x106
transduced R tumor cells were injected s.c. into 129S6 mice and tumor growth was
monitored for 21 days. Data are from at least 3 independent experiments. (G) cDNA
was made from ex vivo isolated R and P tumors as well as transduced R tumor cells
and analyzed for spectrin-β2 as described in (C). (H) Mice bearing R-EV Ctrl, R-
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cMyc, R-PDK1, R-Glut1 and R-HK2 tumors on day 12 were injected i.v. with 100 µg
of 2-NBDG per mouse. Acquisition of 2-NBDG by CD8 TILs and tumor cells was
measured by flow cytometry. Data are presented as 2-NBDG MFI ratios of TILs-totumors. Each dot represents an individual mouse and horizontal bars indicate means
± SEM of 3 independent experiments. **p=0.009 for R-EV Ctrl vs R-cMyc, p=0.0065
for R-EV Ctrl vs R-Glut1, and p=0.0066 for R-EV Ctrl vs R-HK2.
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Figure 5. Enhanced metabolis in antigenic tumors can dictate tumor
progression
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(A) The average tumor growth from all mice injected with either R or R-1% tumor
cells is shown. ***p<0.001. Data are from 3 independent experiments. (B) The
mRNA expression of mutant spectrin-β2 expression in indicated tumors was
assessed. Results are presented as mean ± SEM from 3 independent experiments.
ns, not significant. (C) Cell proliferation rate of transduced R and R-1% tumors were
measured by dilution of CTV at day 0 and 3. The histogram plot is shown from one
experiment. (D) The average tumor growth from all mice injected with transduced REV Ctrl, R-cMyc, R-PDK1, R- Glut1 and R-HK2 tumors is shown. **p<0.01 for all the
tumors in comparison with R-EV Ctrl tumor cells. Data are from ≥3 independent
experiments. (E) CFSE labeled original R, P and R-1% targeted tumor cells were cocultured with C3 T cells for 12h at indicated effector-to-target ratios (E:T) and the
cytotoxicity efficiency analyzed by flow cytometry. (F) Cytotoxic efficiency of C3 T
cells co-cultured with transduced R-EV Ctrl, R-cMyc, R- PDK1 and EL4-Ova tumors
was measured as described in (E). Data (E and F) from 3-5 independent
experiments are presented as the percentage of live target cells normalized to
reference cells (% of survival). (G) Proliferation of indicated transduced tumors was
measured by CTV dilution at day 0 and 3 post-CTV labeling. The histogram plot is
shown from one experiment. (H) 1x106 transduced tumor cells as indicated were
injected s.c. into Rag-/- 129S6 mice and tumor growth was monitored. Data are an
average of two perpendicular diameters ±SEM from at least 3 independent
experiments. (I) Transduced tumor cells were cultured with activated OT-I CD8+ T
cells overnight, and then IFN-γ production was measured after 5h PMA/ionomycin
restimulation. Either no additional glucose or 10 mM glucose was added back to the
media during the restimulation. Representative data are shown as dot plots from 4
independent experiments. Percentage and MFI (blue vertical) values of IFN-γ+ cells
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are shown.
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§ 2.5 Immune checkpoint blockade therapy corrects nutrient restriction
experienced by T cells in a progressing tumor

Immune checkpoint blockade therapy is a revolutionary approach to activate antitumor immunity by targeting proteins that negatively regulate T cell responses (Hodi
et al., 2010, Brahmer et al., 2012, Hamid et al., 2013). This treatment can affect T
cell proliferation (Spranger et al., 2014), function (West et al., 2013, Spranger et al.,
2014) and glucose uptake (Parry et al., 2005), but the precise mechanisms of how
various checkpoint blockade inhibitors work, and why they are effective against
tumors in some patients, but not in others, remain unclear (Page et al., 2014). In
order to investigate whether tumor- imposed nutrient-restriction of T cells is a general
mechanism leading to cancer progression, we decided to test whether checkpoint
blockade therapy influences the metabolic interplay between tumors and T cells in
the tumor microenvironment. We reasoned that since these treatments are effective
at inducing the regression of P tumors (Gubin et al., 2014), we should observe an
effect on tumor/TIL metabolism after treatment if our proposed model of metabolic
competition in the tumor microenvironment was correct. Therefore we transplanted P
tumors into mice and treated with isotype control antibody or CTLA-4, PD-1, or PDL1 blockade antibodies at days 3, 6, and 9 after transplantation and assessed
metabolic parameters and TIL function on day 12 (Figure 6A). We also transplanted
R tumors into mice and treated with isotype control antibodies as a control for
regression. As expected (Gubin et al., 2014), we found that treatment with antibodies
against CTLA-4, PD-1, or PD-L1 all resulted in control of P tumors (Figure 6B).
Isotype control antibodies had no effect on the outcome of P or R tumor cell growth
(Figure 6B). We excised tumors at day 12 and measured glucose concentrations in
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the extracellular milieu and found that the tumors from blockade antibody-treated
mice had significantly more available extracellular glucose (similar to the
concentrations found in the R tumors) when compared to isotype antibody-treated
control mice (Figure 6C). In addition, TILs from the blockade antibody treated mice
displayed enhanced ECAR in comparison to TILs isolated from P tumors of isotype
control treated mice (Figure 6D). These data indicated that glucose availability in the
tumor microenvironment correlated with the glycolytic capacity of TILs. To confirm
that TILs in checkpoint blockade antibody-treated mice were in a nutrient-sufficient
state, we examined their mTOR pathway activity on day 12 post-transplantation. We
observed that mTOR activity, measured by the phosphorylation of 4E-BP1, S6K and
S6, of TILs in P tumors from mice receiving blockade antibodies was restored to a
level closer to that measured in TILs from R tumors (Figure 6E). Finally, we found
that the increased glucose available in the tumor, and the greater ECAR observed in
TILs, correlated with increased IFN-γ production by the TILs after checkpoint
blockade therapy (Figure 6F). Together these data suggest that nutrients in the
tumor microenvironment dictate the nutrient status of activated T cells and that this
influences their effector function. Furthermore, our data indicate that checkpoint
blockade therapy corrects the tumor- induced glucose restriction experienced by
TILs and restores their glycolytic capacity and hence their ability to produce IFN-γ.
These data support the notion that glucose concentration in a tumor can be a
determining factor for T cell effector function. In addition to being converted to
lactate, pyruvate made by glycolysis can also enter the mitochondria and be
converted to acetyl-CoA, which can enter the TCA cycle and support the generation
of substrates for oxidative phosphorylation (OXPHOS). We reasoned that changes in
glucose availability might be reflected in changes in TIL OXPHOS as well as aerobic
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glycolysis. By plotting OCR (oxygen consumption rate, a measure of OXPHOS) vs.
ECAR (the measure of aerobic glycolysis), we established a baseline value for
metabolic fitness of TILs from R vs. P tumors; this measurement emphasized that
TILs from R tumors have higher OXPHOS as well as aerobic glycolysis compared to
TILs from P tumors (Figure 6G). We found that CTLA-4 and PD-1 blockade
antibodies not only increased ECAR, but also increased OCR in the TILs from P
tumors, to levels equal or above those observed in TILs in the R tumor, indicating
that these treatments enhanced the overall metabolic fitness of the TILs (Figure 6G).
PD-L1 blockade antibodies, however, primarily promoted aerobic glycolysis, rather
than OCR, in the TILs (Figure 6G).
We speculated that in addition to augmenting the capacity of TILs to compete for
glucose to support OXPHOS and aerobic glycolysis, checkpoint blockade treatment
might increase the ability of TILs to compete for other substrates. We assessed the
protein expression of glutamate dehydrogenase (Glud1), a mitochondrial enzyme
that catalyzes the oxidative deamination of glutamate to α-ketoglutarate, an
important process for energy homeostasis in T cells (Wang et al., 2011) .We found
that Glud1 expression was increased in TILs in the P tumor that had been treated
with PD-L1 blockade antibodies (Figure 7A). These data support the idea that, in
addition to glucose, competition for amino acids, and possibly other nutrients and
growth factors not examined here, occurs within a tumor microenvironment, and
emphasize the fact that checkpoint blockade broadly increases the metabolic fitness
of TILs and supports the view that this may be central to the beneficial effects of
these treatments in cancer therapy.
Given that checkpoint blockade therapy leads to tumor regression (Figure 6B), we
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speculated that the enhanced glucose levels in the tumors of treated mice were a
result of immune-mediated killing, which would lead to a reduction in the total
number of tumor cells and thus a reduction in total glucose consumption within the
tumor. It is known that blocking inhibitory receptors enhances T cell activation (Keir
et al., 2008, Francisco et al., 2010), and we speculated that this might reflect the fact
that these treatments allow T cells to better compete for nutrients like glucose in the
microenvironment, allowing a greater engagement of glycolysis by TILs when
competing directly against the tumor. Consistent with this idea, and with published
reports (Parry et al., 2005, Staron et al., 2014, Pedicord et al., 2015), we found that
even treating in vitro activated T cells, which are already highly glycolytic, with
checkpoint blockade antibodies against PD-1 and CTLA-4, further increased their
ECAR, although the effects were small (Figure 7B, C). These results could suggest
that treatments that block negative signals to T cells in vivo may, in part, work by
enhancing their ability to compete for nutrients in the tumor and engage aerobic
glycolysis.
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Figure 6. T cells in progressing tumors regain glycolytic capacity and effector
function after checkpoint blockade therapy
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(A) Naïve mice (n=6-8) were injected s.c. with R or P tumor cells followed by
treatment with anti-CTLA-4 (αCTLA-4), anti-PD-1 (αPD-1), anti-PD-L1 (αPD-L1)
blockade antibodies, or isotype control (Iso) antibody at days 3, 6 and 9 after tumor
inoculation and tumor growth was monitored. (B) Tumor size is shown as an average
of two perpendicular diameters ± SEM of at least 3 independent experiments. (C-E)
Tumors were removed at day 12 after transplantation, and glucose concentrations in
the extracellular milieu of ex vivo tumors were measured (C). Data are normalized to
R tumors treated with isotype control antibody and depict mean ± SEM from 1–3
independent experiments. *p=0.0208, **p=0.0015 (R vs. P-Iso), **p=0.0024,
***p=0.001. (D) ECAR of TILs, isolated after checkpoint blockade therapy. Data are
normalized to R tumors treated with isotype control antibody and depict mean ± SEM
from 3 independent experiments. ***p<0.001. (E) Phosphorylation of 4E-BP1, S6
and S6K in TILs were measured by flow cytometry. Bar graphs (left) are shown as
the mean ± SEM from 4 independent experiments, and histograms (right) are
representative of 4 independent experiments. p4E-BP1: *p=0.0249, **p=0.0047
(αCTLA-4), **p=0.0050 (αPD-1). pS6K: **p=0.0024 (αCTLA-4), **p=0.0025 (αPDL1). pS6: *p=0.0145 (αCTLA- 4), *p=0.015 (αPD-1), *p=0.0134 (αPD-L1). (F) IFN-γ
production of TILs was examined after 5h restimulation with PMA/ionomycin. The
percentage of IFN-γ+ cells is depicted on the top left and the MFI of IFN-γ+ cells is
shown vertically as indicated. Data are representative of 3 independent experiments.
(G) OCR versus ECAR (mean ± SEM for both parameters) of TILs, isolated after
checkpoint blockade therapy. Data are from 3 independent experiments.
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Figure 7. Effects of checkpoint antibodies on T cell metabolism

(A) Expression of Glud1, LDHa and p4E-BP1 of CD8 TILs in P tumor cells were
examined by western blot. Data are representative from 2 independent experiments.
Naïve CD8+ T cells were activated with anti-CD3/28 for 3 days and then were treated
with 10 µg/ml of either anti-CTLA-4 (αCTLA-4) (B) or anti-PD-1 (αPD-1) (C) blockade
antibodies, or Isotype control antibody for 24h. ECAR of the T cells was measured.
Data are shown as mean ± SEM from 3 independent experiments.
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§ 2.6 PD-L1 directly regulates tumor metabolism

PD-L1 expression is induced on tumor cells in response to IFN-γ produced by T
cells, and the upregulation of PD-L1 is a mechanism that allows the tumor to evade
immune mediated attack by inhibiting T cell function through PD-1/PD-L1 interaction
(Keir et al., 2008, Francisco et al., 2010). While there is a strong correlation between
PD-L1 expression on melanomas and T cell infiltration (Quezada and Peggs, 2013),
this is not the case for every cancer. For example, it has been shown that patients
with glioblastoma often have high PD-L1 expression, but this expression does not
correlate with levels of TILs observed in the tumors (Berghoff et al., 2015). It has
also been shown that expression of PD-L1 on neurons can, through an unknown, but
immune system independent mechanism, kill glioblastoma cells (Liu et al., 2013).
Furthermore, another study showed that cancer cell expression of PD-L1 mediated
killing of T cells in vitro, an effect that occurred independently of PD-1 (Dong et al.,
2002). Collectively, these results made us consider the possibility that PD-L1 could
have an additional function beyond its role in providing negative signals to T cells as
a ligand to PD-1. We therefore hypothesized that blocking PD-L1 on tumor cells
might directly alter tumor cell metabolism. We incubated R and P tumors with PD-L1
blockade antibody overnight and then measured the ECAR of the cells. We found
that the ECAR of the P tumor cells, as well as glucose uptake as indicated by 2NBDG acquisition, were reduced when the cells were treated in vitro with PD-L1
blockade antibody, compared to those cells treated with the isotype control antibody
(Figure 8A, B). R tumor cells, which display lower ECAR in comparison to P tumor
cells, showed a smaller reduction in ECAR when treated with anti-PD-L1 (Figure
8A). Antibodies against major histocompatibility complex-I (MHC-I), another surface
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protein expressed by P tumors, did not affect ECAR (Figure 9A). We next tested
whether PD-L1 blockade would inhibit ECAR in other tumor types. We found that
PD-L1 blockade significantly inhibited ECAR in B16 melanoma, MC38 colon cancer,
as well as L cells and other progressor-type clones derived from the d42m1 parent
sarcoma (Figure 9B). Of note, ECAR was dampened to varying degrees across
these cell lines, suggesting that there is differential sensitivity to this treatment
among tumors. Our results suggested that PD-L1 had an additional and previously
unrecognized role in the regulation of tumor cell glycolytic metabolism. Therefore, we
examined the link between PD-L1 and glycolysis. Since mTOR is a sensor of nutrient
status, and this kinase integrates input from upstream pathways (Laplante and
Sabatini, 2012), we assessed whether treatment with anti-PD-L1 modulated the
activity of mTOR target proteins in the P tumor cells. We treated P tumor cells with
anti-PD-L1 and observed decreased phosphorylation of critical mTOR target proteins
(Figure 8C and Figure 9C), which correlated with reductions in ECAR.
We next assessed the consequences of dampened mTOR signaling resulting from
anti-PD-L1 treatment. Given that mTOR directly regulates mRNA translation and
ribosome biogenesis (Laplante and Sabatini, 2012), and that we observed a
reduction in ECAR following anti-PD-L1 treatment (Figure 8A), we analyzed
expression of several glycolysis enzymes after PD-L1 blockade. Moreover, since
growth factors signal to mTOR via Akt, we also assessed Akt phosphorylation. We
found that the expression of glycolysis enzymes, and Akt phosphorylation, were
decreased after anti-PD-L1 treatment (Figure 8D and 9D). Consistent with the idea
that mTOR can affect the glycolysis pathway by regulating the translation of mRNAs,
there were no differences in levels of transcripts from key glycolysis pathway genes
following anti-PD-L1 treatment (Figure 9E), even though the protein levels were
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decreased. These data suggest that PD-L1 regulates the Akt/mTOR pathway, which
results in decreased translation of transcripts for glycolysis pathway enzymes, and
thus dampened glycolysis.
Since PD-L1 has only been shown to have a clear function when signaling through
PD-1, we next wanted to determine how the PD-L1 blockade antibody could dampen
mTOR signals in our in vitro system, which is devoid of T cell-expressed PD-1. We
reasoned that antibodies against PD-L1 could be causing PD-L1 internalization and
resultant cessation of events downstream of PD-L1. After treating cells with anti-PDL1 blockade antibody for 30 minutes at 37°C, we found that PD-L1 had moved from
the surface to the interior of the cell (Figure 8E), indicating receptor internalization
and a reduction of surface PD-L1 expression (Figure 9F). These results suggest that
PD-L1 surface expression is important for the enhancement of Akt/mTOR signaling
in tumor cells.
To confirm that PD-L1 can regulate glycolysis, we asked whether genetic loss of
function of PD-L1 could affect glycolysis and nutrient sensing pathways in tumor
cells. Using a retrovirus expressing a short-hairpin (hp) RNA against PD-L1 to
decrease PD-L1 expression in P tumors, we found that ECAR, mTOR pathway
activity, Akt activity, and glycolysis enzyme expression were all reduced in cells
expressing PD-L1 shRNA (PD-L1 hp) compared to cells expressing a control hairpin
(Ctrl hp) (Figure 8F-H and Figure 9G). P tumors expressed higher PD-L1 than R
tumors (Figure 8I, upper panel), which correlated with their enhanced ECAR (Figure
1D, G), glucose uptake (Figure 1B, J), and thus glycolysis. Importantly, along with
decreased ECAR, PD-L1 shRNA decreased PD-L1 expression (Figure 8I, lower
panel), but did not affect cell proliferation in vitro (Figure 9H), nor did it affect tumor
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growth rate when transplanted in vivo into RAG-/- mice (Figure 9I), suggesting that
neither PD-L1, nor the glycolysis pathway, is necessarily coupled to tumor cell
proliferation. To further verify that PD-L1 expression on tumors modulated the
glycolytic pathway, we used a genetic gain of function approach, and used retroviral
transduction to generate R tumor clones that expressed different levels of PD-L1
(high and low), which were sorted for subsequent analysis. We found that high PDL1 expressing R tumors had elevated ECAR compared to low PD-L1 expressing
tumors (Figure 8J). Together our data indicate that PD-L1 expression in tumor cells
is directly associated with their glycolytic rate, and that PD-L1 engagement by mAbs
can modulate glycolytic metabolism in tumor cells.
Our results suggest that PD-L1 is immunomodulatory, not only because it delivers a
negative signal to T cells via PD-1 (Keir et al., 2008, Spranger et al., 2014), but also
because it enhances tumor cell glycolysis and thus takes away available glucose
from invading immune cells in the tumor microenvironment. To further support the
idea that PD-L1 can modulate tumor cell metabolism directly, independently of the
adaptive immune system, we transplanted PD-L1 expressing tumors into RAG-/mice. We then treated these mice with PD-L1 blockade or isotype control antibodies.
At day 12, we excised tumors and measured glucose concentrations in the
extracellular milieu. We found that there was significantly more available glucose in
the tumor microenvironment of tumors isolated from mice that received PD-L1
blockade antibody as compared to tumors from isotype control antibody treated mice
(Figure 8K). Importantly, anti-PD-L1 treatment of PD-L1-expressing tumors in RAG-/mice had only a minor effect on reducing tumor size (data not shown), supporting the
view that in immunocompetent mice, T cell mediated clearance of tumors is critical
(Matsushita et al., 2012, Gubin et al., 2014). Taken together our results show that
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expression of PD-L1 on the cell surface, maintains Akt/mTOR signaling in tumors,
which in turn supports the translation of glycolysis enzymes, thus promoting this
metabolic pathway. Our data further show that PD-L1 blockade therapy reduces
surface expression of PD-L1 on tumors and inhibits their glycolytic capacity, thereby
leaving more available glucose in the extracellular tumor milieu.
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Figure 8. PD-L1 promotes mTOR activity and glycolytic metabolism in tumor
cells
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R or P tumor cells were treated with IFN-γ for 48h followed by 10 µg/ml of PD-L1
blockade (αPD-L1) or isotype control (Iso) antibodies for 24h. (A) ECAR posttreatment was assessed. Data from ≥5 independent experiments are shown as
relative ECAR normalized to R tumors treated with isotype control antibody.
***p=0.0001. (B) Acquisition of 2-NBDG by tumor cells was measured by flow
cytometry. Data are from 3 independent experiments and are normalized to the MFI
values of the R tumor. ***p=0.001. (C) Phosphorylation of 4E-BP1, S6K and S6 was
analyzed by western blot, data are representative of 3 independent experiments.
Representative histogram plots of phosphorylated 4E-EP1 and S6K assessed by
flow cytometry below. (D) Phosphorylation of AKT and glycolytic enzymes PGK1 and
LDHa were examined by western blot. Data are representative of 2 independent
experiments. (E) R tumor clones overexpressing high levels of PD-L1 were treated
with PD-L1 antibody (αPD-L1) for 15 minutes on ice, then either kept on ice (0 min)
or incubated at 37°C for 30 minutes (30 min). The cells were then either washed in
an acid solution to dissociate antibody from the surface of the cells (+ acid wash) or
left untreated (no acid wash). After fixation, cells were incubated with anti-Rat IgG
A488 (red) to detect αPD-L1 present on the surface of the cells, then following
permeabilization the cells were incubated with anti-Rat IgG A647 (yellow) to detect
both surface expressed and internalized αPD-L1. Following staining with a nuclear
stain (blue), cells were imaged by confocal microscopy. Data are representative of 4
independent experiments. (F) Tumor cells were transduced with pdl1 shRNA (PD-L1
hp) or control hp against luciferase (Ctrl hp) and ECAR of transduced tumor cells are
shown (from 2 independent experiments represented as relative ECAR normalized
to P Ctrl transduced tumor cells), ***p<0.0001. (G) Phosphorylation of 4E-BP1, S6,
and S6K was examined by western blot. Data are representative of 3 independent
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experiments. (H) Phosphorylation of AKT, total AKT, and glycolytic enzymes PGK1,
LDHa, TPI were examined by western blot. Data are representative of 3 independent
experiments. (I) PD-L1 expression on R or P tumors pre-treated with IFN-γ for 48h
(top panel). PD-L1 expression on tumor cells transduced with PD-L1 hp or Ctrl hp
and treated with anti-PD-L1 for 24 hours (bottom panel). (J) ECAR of R tumors
expressing high (Hi) and low (Lo) levels of surface PD-L1 after transduction with a
PD- L1 expressing retroviral construct. Data are represented as mean ± SEM (error
bar) of 2 independent experiments. (K) Rag KO mice were injected s.c. with 2x106 RPD-L1 expressing tumor cells, followed by treatment with PD-L1 blockade antibodies
(αPD-L1) at days 2, 5, 8 and 11 after transplantation. Tumors were removed at day
12 and extracellular glucose concentrations were measured. Data are from 2
independent experiments. *p=0.0319.
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Figure 9. PD-L1 directly regulates tumor cell metabolism
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(A) ECAR of P tumor cells treated with IFN-γ for 48h followed by 10 µg/ml of either
MHC-I or anti-PD-L1 (αPD-L1) blockade antibodies for 24 hours. Data show ECAR
at baseline and after injection of the mitochondrial ATP synthase inhibitor oligomycin
and are representative of 3 independent experiments. (B) ECAR of B16, MC38 and L
tumor cells pre-treated with IFN-γ for 48h followed by PD-L1 blockade antibody for
24 hours was measured. Multiple tumor progressor clones—T10, ES1, ES2 and
ES3—derived from parental d42m1 tumor cells were treated with anti-PD-L1 or
isotype control antibodies and their ECAR was measured 24h after treatment. Bar
graph shows the mean ± SEM and generated from the results of 3 independent
experiments.

*p=0.0255,

***p=0.001.

(C)

Western

blot

analysis

for

the

phosphorylation of mTOR targets (p4EB-P1, pS6K, and pS6) on P tumor cells
treated with αPD-L1 blockade antibody. (D) Phosphorylation of Akt and glycolytic
enzymes PGK1, LDHa, and TPI were examined by western blot. Blots (C and D) are
representative of 3 independent experiments. (E) mRNA expression of glycolytic
enzymes (HK2, LDHa, PDK1, and TPI) in P tumor cells treated with or without antiPD-L1 antibody (αPD-L1). qPCR data are generated from 3 independent
experiments and shown as mean ± SEM, n.s., not significant. (F) The R tumor clone
overexpressing high level of PD-L1 was treated with αPD-L1 antibody for 30 minutes
(30 min). The cells were then either either washed in an acid solution to dissociate

75

antibody from the surface of the cells (+ acid wash) or left untreated (no acid wash).
After fixation, cells were incubated with anti-Rat IgG A488 (Detect surface PD-L1) to
detect anti-PD-L1 present on the surface of the cells, then following permeabilization
the cells were incubated with anti-Rat IgG A647 (Detect PD-L1 after perm) to detect
internalized anti- PD-L1. PD-L1 expression was assessed by flow cytometry. Data
are representative of 4 independent experiments. (G) Western blot analysis of R and
P tumors transduced with pdl1 shRNA (PD-L1 hp) or Control hp against luciferase
(Ctrl hp) for the phosphorylation of mTOR targets (left), and Akt and glycolysisrelated enzymes Akt, PGK1, and TPI (right). Blots are representative of 4
independent experiments. (H) Cell proliferation rate of transduced R and P tumors in
(F) were measured by the dilution of CTV at day 0 and 3. The histogram plot is
representative of 3 independent experiments. (I) 1x106 transduced tumor cells as
were injected s.c. into Rag-/- 129S6 mice and tumor growth was monitored. Data are
an average of two perpendicular diameters ± SEM from one experiment (n=4).
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§ 2.7 Discussion

Antigen recognition by T cells is critical for tumor clearance, and stronger antigens
lead stronger activation (Lanzavecchia and Sallusto, 2002, Rao et al., 2010) and a
greater capacity to compete for nutrients. T cells must adequately compete for
nutrients in order to engage the metabolism that supports their function. We (Chang
et al., 2013, O'Sullivan and Pearce, 2015, Pearce et al., 2013), and others (Mellor
and Munn, 2008, Srivastava et al., 2010, Mockler et al., 2014), have speculated that
nutrient competition in the tumor microenvironment in vivo impacts T cell function.
We establish here that tumors can dampen TIL function by competing for glucose,
even when antigens that are strongly recognized by T cells are expressed by the
tumor, demonstrating that metabolic competition, as a distinct mechanism, can lead
to T cell hyporesponsiveness during cancer. Our data also support a model where
the competition for other nutrients or growth factors beyond glucose could also
present a similar metabolic competition in tumors.
It makes biological sense that nutrient competition in a tumor shapes the ability of
immune cells to perform in that environment. T cells are primed in lymphoid tissues,
which are likely nutrient-replete. Upon activation, T cells traffic to sites of
inflammation where they have to compete with other diverse cell types for available
resources. When activated T cells, which need to engage aerobic glycolysis for
effector function (Cham et al., 2008, Jacobs et al., 2008, Chang et al., 2013),
infiltrate a tumor, we suggest that they experience a nutrient deprivation that impairs
their function, but not necessarily their survival, and this can lead to T cell
hyporesponsiveness and cancer progression. Consistent with this idea, it was
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recently shown that TILs that are specific for defined P tumor antigens infiltrate the P
sarcoma prior to checkpoint blockade therapy, however these cells lack function and
do not produce IFN-γ until after checkpoint blockade therapy is administered (Gubin
et al., 2014). These results support our hypothesis, and suggest that conditions in
the microenvironment, even when antigen is recognized, can impose T cell
hyporesponsiveness. This view is consistent with the idea that T cell activation and
costimulatory signals, first and foremost, remodel the metabolism in the T cell, and
endow the cell with new features that allow it to more efficiently compete for
nutrients, e.g. enhanced glucose transporter (Glut1) expression (Jacobs et al.,
2008). It is not merely coincidental that signaling through CD28 – the very process
that prevents T cell anergy – primarily functions to increase glucose uptake
(Frauwirth et al., 2002). It is also possible that cells such as Treg cells and M2polarized macrophages, neither of which require aerobic glycolysis, but instead use
fatty acid oxidation (Vats et al., 2006, Michalek et al., 2011, Huang et al., 2014),
often appear in progressing tumors because these are cells that are likely able to
metabolically compete and survive well in a low glucose environment. This is also
consistent with observations that M1-polarized macrophages and effector T cells,
both of which require aerobic glycolysis (Pearce et al., 2013) for function, appear in
regressing tumors, which we presume to be relatively glucose-replete.
Our data suggest that glucose, which is primarily thought to be stably regulated and
abundantly available in metazoan organisms, can actually become a limiting factor
for T cells in the tumor microenvironment. Our experiments show that there are
differences between tumors in their acquisition of glucose, and that these differences
do not necessarily relate to differences in their proliferation. When considering how
glucose depletion alters T cell function, it is intriguing to speculate that enhanced
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glucose acquisition, and even glycogen storage, is selected for within tumors
(Favaro et al., 2012) as these traits could act to deprive T cells of glucose and thus
reduce the effectiveness of the antitumor T cell response. Our understanding of how
the competition for resources, including basic nutrients, is dynamically regulated in a
particular niche in an animal, and how this can impose functional changes in cells, is
only just beginning to develop. Tumor-imposed nutrient restrictions are of course not
limited to glucose. Availability of amino acids, fatty acids, other metabolites like
lactate, and the presence of growth factors and co-stimulatory signals that dictate
whether T cells will express the appropriate transporters to allow nutrient acquisition
will all influence T cell function in the tumor (Pearce et al., 2013, Mockler et al.,
2014). Furthermore, other cell types, especially other immune cells in the tumor
microenvironment, will not only impact, but may actively shape the metabolic
balance between tumors and effector T cells, vastly affecting the immune response
outcome.
We showed previously that aerobic glycolysis is required for T cells to attain full
effector status and that this occurs via a posttranscriptional mechanism that involves
the bi- functional enzyme GAPDH. When glucose is present, GAPDH is engaged in
its enzymatic function in the glycolysis pathway; when cells are restricted from
glucose, GAPDH leaves the glycolysis pathway and binds the 3’UTR of IFN-γ mRNA
and prevents its efficient translation (Chang et al., 2013). We found that when T cells
are glucose restricted for short periods of time, their dampened cytokine production
can be rescued by re-feeding the cells glucose, as GAPDH will become re-engaged
in the glycolysis pathway. However, our preliminary observations indicate that if T
cells experience prolonged chronic nutrient deprivation, this dampened cytokine
production becomes relatively irreversible, leading to a more permanent dysfunction
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that cannot be corrected through simple re-exposure to nutrients. These data
suggest that therapeutic strategies to simply elevate glucose in an established tumor
microenvironment would not necessarily be effective in reversing the hyporesponsive
phenotype of TILs. Not only might TILs be unable to respond to glucose readily, for
example, if they have not maintained expression of the glucose transporter, but if the
metabolic balance between the tumors and TILs is not perturbed in favor of the T
cells prior to exposure to glucose, then the tumor will likely continue to outcompete
the T cells, even in the presence of more available glucose (O'Sullivan and Pearce,
2015). Current studies in our laboratory are aimed at understanding how initial
metabolic restrictions in vivo can set the scene that leads to long-term
hyporesponsiveness in T cells.
We envisage that the various states of T cell hyporesponsiveness that have been
described in cancer and infection may be induced by an initial metabolic restriction.
This could manifest from a simple shortage of glucose, as we suspect is the case
when a tumor outcompetes T cells for this nutrient, or any signal, or lack of signal, to
the T cell that abrogates its ability to acquire glucose. The latter situation provides a
mechanism for how these events could occur even when glucose itself is not limiting.
If this model were correct, then it might suggest that there is only a short window of
time when T cells already present in a tumor could be targeted to regain functional
capacity. Therefore, strategies that aim to deplete immune cells in a tumor, coupled
with those that aim to promote glycolysis in newly infiltrating T cells may be the most
effective way to metabolically remodel the tumor microenvironment. It is conceivable
that checkpoint blockade therapy against CTLA-4, which is now known to deplete
Treg cells in tumors (Simpson et al., 2013) may work in part by creating space in the
tumor that permits the influx of newly activated cells. Combining checkpoint blockade
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therapies that target CTLA-4 with those against PD-1 may further amplify the
metabolic alterations in the tumor by enhancing the activation of the infiltrating T
cells as they enter the newly created, and more nutrient replete, environment.
Perhaps highlighting why, at least in part, these combined therapies are proving so
successful in patients (Hamid et al., 2013, Wolchok et al., 2013).
Our data showing that checkpoint blockade antibodies restore the glucose balance in
the P tumor microenvironment suggest that these therapies might be most effective
against tumors with higher glycolytic rates. It is likely that progressor tumors with low
rates of glycolysis, such as those that rely predominantly on OXPHOS, and perhaps
even use other diverse substrates for fuel, do not starve the microenvironment of
glucose as drastically as those tumors that engage glycolysis highly, and thus would
be less affected by these therapies. If this were the case, then it could perhaps
explain why these therapies work for some patients, but not for others. We are
currently investigating whether the glycolytic rate of a tumor could be used as a
prognostic tool to determine the efficacy of these treatments.
Our finding that surface expressed PD-L1 directly regulates tumor cell glycolysis was
serendipitous. Enhanced PD-L1 expression on tumor cells correlates with dampened
immune responses and tumor progression (Keir et al., 2008), and PD-L1 is known to
inhibit T cells via PD-1, but it has remained unclear whether PD-L1 expression by
tumor cells serves additional biological advantages for malignant tumors to establish
and grow. Consistent with our findings that PD-L1 has T cell independent function, it
has been shown that neurons can inhibit the proliferation of astrocytoma cells in coculture (Hatten and Shelanski, 1988), and that killing of murine glioblastoma cells is
dependent on expression and activity of PD-L1 receptor on neurons (Issazadeh-
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Navikas, 2013, Kingwell, 2013). The precise mechanism by which these events
occur is not known, however these observations might possibly be explained if PDL1 expression conferred a higher glycolytic metabolism to one cell type, e.g.
neurons, that allowed them to deplete glucose from, and subsequently lead to the
dampened survival of another cell type, e.g. cancer cells. In fact, induction of PD-L1
expression by neurons in tumor-adjacent brain tissue associates positively with
glioblastoma patient survival, whereas lack of neuronal PD-L1 expression is
associated with high PD-L1 in tumors and unfavorable prognosis (Liu et al., 2013).
Intriguingly, the fact that PD-1 blockade increased OXPHOS and aerobic glycolysis
in TILs, while PD-L1 blockade only increased aerobic glycolysis might suggest that
these treatments work through distinct mechanisms to promote TIL function in vivo,
but more investigation is needed to determine if this is the case.
The 30 amino acid cytoplasmic tail of PD-L1 is highly conserved across species,
which suggests functional significance, however it has not yet been characterized to
possess any signaling capacity (Keir et al., 2008, Francisco et al., 2010). Our data
show that PD- L1 shRNA-mediated knockdown, which results in decreased overall
PD-L1 expression, phenocopies our results with PD-L1 blockade antibody, which
causes decreased expression of surface PD-L1 via receptor internalization. These
data suggest that this protein must be expressed on the cell surface for its function.
Current experiments are underway to identify precisely how surface expressed PDL1 is signaling to Akt and mTOR, and which other proteins might be involved in this
process. It is conceivable that the cytoplasmic tail of PD-L1 is phosphorylated
directly and when this occurs, it interacts with other proteins that relay information to
mTOR. Likewise, it is also possible that PD- L1 sits in a domain in the cell membrane
that promotes its association with other signaling proteins. This association would
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not necessarily be dependent on any signaling capacity inherent to the cytoplasmic
domain, but rather accessory proteins could relay a signal to mTOR. We envisage
that in this situation, if PD-L1 is not expressed at the surface, then the association
with other proteins in the membrane is destabilized, and signaling to mTOR is
blunted. Regardless of the precise sequence of events that transduces the signal
from PD-L1 to the mTOR pathway, we have clearly shown that this molecule has a
novel function in regulating tumor cell metabolism.
In summary, we have shown that glucose competition between tumors and T cells
can directly influence cancer progression, and have discovered an unexpected role
for PD- L1 in directly regulating the metabolic state of tumor cells. New efforts to
target cancer should incorporate the idea that metabolic competition occurs in
tumors and that this greatly influences tumor progression. In light of these findings,
future therapies may consider combining treatments that dampen tumor cell
metabolism with those that enhance glycolytic capacity in TILs in order to promote
optimal anti-tumor immunity.
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Figure 10. Summay model of nutrient competition in tumor microenvironment
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CHAPTER 3

ACETATE RESCUES T CELL HYPORESPONSIVENESS INDUCED
BY NUTRIENT RESTRICTION
(Manuscript submitted for review)
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§ 3.1 Introduction

Metabolic fitness is intimately linked with T lymphocyte survival, differentiation, and
function. T cells use glucose and glutamine as their primary fuel source for energy
generation (Bental and Deutsch, 1993). Naïve T cells are quiescent and break down
glucose to fuel oxidative phosphorylation (OXPHOS). Upon activation, T cells
undergo rapid metabolic reprogramming and augment aerobic glycolysis, in which
glucose is metabolized into pyruvate and then converted to lactate, generating 2
molecules of ATP despite the presence of adequate oxygen. These metabolic
changes support their extensive cell growth, proliferation, and cytokine production
allowing a functional immune response against infection and cancer. This dramatic
increase of glycolysis requires increased glucose uptake by T lymphocytes, which is
controlled by cell-surface expression as well as the trafficking of Glut-1, a glucose
transporter primarily expressed on T lymphocytes (Frauwirth et al., 2002, Wood et
al., 2003, Scheepers et al., 2004, Cham et al., 2008). An inability to access sufficient
nutrients poses a significant barrier to effector T cell function. Culture of T cells in
glucose-limiting conditions has been shown to inhibit mTORC1 signaling and gene
expression, thus impairing cell adhesion, proliferation and survival of CD8 T cells, as
well as the production of effector molecules including interferon-gamma (IFN-γ)
(Cham et al., 2008, MacIver et al., 2013). CD4 T cells from fasting animals also
exhibited long-lasting metabolic and functional defects in a leptin dependent manner
(Saucillo et al., 2014). When effector T cells disengage from glycolysis, the enzyme
glyceraldehyde-3-phosphate dehydrogenase (GADPH) switches functionally from a
metabolic enzyme to a mRNA binding protein that preferentially binds to 3’
untranslated regions (UTR) of cytokine mRNAs, preventing their translation. (Nagy
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and Rigby, 1995, Chang et al., 2013). In addition, inhibition of glycolysis can lead to
increased expression of immune regulatory receptors, such as program death-1 (PD1), which has been reported as an early driver of T cell exhaustion due to altered
metabolism (Wherry, 2011, Patsoukis et al., 2015, Wherry and Kurachi, 2015,
Bengsch et al., 2016) Naïve cells deprived of glucose enter a state of metabolic
anergy even in the presence of adequate TCR engagement and stimulatory signals
(Zheng et al., 2009). Finally, nutrient availability in tissue microenvironments may
also impact T cell function. Studies from our group indicate that infiltrating T cells in
the tumor microenvironment compete with tumor cells for available glucose and this
nutrient restriction directly dampens their mTOR activity, glycolytic capacity, and IFNγ production, leading to tumor progression (Chang et al., 2015).
Acetate has gathered increased attention as both a carbon source for cellular
biomass synthesis and an epigenetic regulator of posttranslational protein
modification (Wang et al., 2010, Zhao et al., 2010, Hosios and Vander Heiden, 2014,
Jaworski et al., 2016). In the context of cancer where glucose and oxygen may be
limiting resources, acetate is a primary source of acetyl-CoA, which is the key
metabolic intermediate for lipogenesis and protein acetylation (Yoshii et al., 2009,
Comerford et al., 2014, Schug et al., 2015, Bulusu et al., 2017). In addition to tumor
cells, acetate also has a major impact on immune cells. Synthesis of acetate from
ethanol is critical for enhancement of the inflammatory response in macrophages
through the increased acetylation of proinflammatory gene histones in acute
alcoholic hepatitis (Kendrick et al., 2010). A recent study also described that a
systemic increase in acetate levels induced by stress is required for optimal memory
CD8+ T cell function (Balmer et al., 2016).
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Changes in cellular metabolism due to nutrient limitation can link to alternations in
gene expression through transcriptional/posttranscriptional regulation networks,
which coordinate with T cell dysfunction or hyporesponsiveness (Hentze et al., 2010,
Castello et al., 2012). However, exactly how T cells respond to external nutrients and
how this shapes their effector function through alternation of metabolic pathways
remains unclear. We set out to determine why T cell hyporesponsiveness due to
short-term glucose restriction can be rescued by glucose re-exposure, while T cells
restricted from glucose for longer periods of time cannot be rescued by this
substrate.
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§ 3.2 Glucose restriction limits T cell glycolysis and dampens effector cytokine
production

Our previous studies indicate that a competition for metabolic resources exists within
the tumor microenvironment. Tumor infiltrating T cells (TILs) can experience glucose
deprivation imposed by tumor cells, which dampens their mTOR activity, lowers their
glycolytic capacity, and impairs their cytokine production, leading to cancer
progression (Chang et al., 2015). Although our study suggests a distinct mechanism
that contributes to T cells hyporesponsiveness during cancer, a fundamental
understanding about the extent environmental changes influence T cell metabolism,
the impact of this metabolic reprogramming on T cell differentiation and function over
time, and ultimately the outcome of T cell mediated immune responses under these
conditions remains unclear. In order to understand how T cells metabolically adapt to
nutrient restrictive environments, we started with a simple in vitro model by activating
naive OT-I T cells with OVA peptide in complete media containing 25mM glucose for
3 days. We used this high concentration of glucose because T cells will produce
higher levels of cytokines at higher glucose concentrations. Activated CD8+ T cells
were then either maintained in 25mM glucose media or switched to glucose-limiting
media containing only 1mM glucose for either 2 more (day 5), 4 more (day 7), or 6
more (day 9) days (Figure 12A). To answer whether nutrient restriction could induce
T cell hyporesponsiveness, we measured IFN-γ production from cultured effector
CD8+ T cells and found that cytokine production was dampened in cells subjected to
1mM glucose media compared to those in 25mM glucose media after PMA and
ionomycin restimulation, consistent with TILs isolated from nutrient restrictive tumors
(Figure 11A) (Chang et al., 2015). Their ability to produce IFN-γ continued to
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gradually wane as they were subjected to prolonged glucose restriction (Figure
11A). PD-1 molecule expression has been well defined as an indicator of T cell
exhaustion or hyporesponsiveness during chronic infection and cancer (Crawford et
al., 2014, Wherry and Kurachi, 2015). To further validate whether hyporesponsive T
cells developed during extended glucose restriction in vitro, we examined surface
expression of PD-1 and found that the level of PD-1 on acutely glucose-restricted T
cells was relatively similar to their counterparts in 25mM glucose but significantly
higher after longer-term glucose deprivation (Figure 11B), consistent with their
hyporesponsive phenotype of impaired IFN-γ production.

Effector T cells need to engage glycolysis for optimal cytokine production(Chang et
al., 2013). We predicted that defective IFN-γ production by glucose restricted T cells
was due to their inability to engage sufficient glycolysis. We performed mitochondrial
stress test assays and confirmed that the extracellular acidification rate (ECAR,
correlates with glycolysis) was lower, but the ratio of oxygen consumption rate (OCR,
correlates with OXPHOS) to ECAR was higher in T cells switched to culture in 1mM
glucose than those in 25mM glucose, indicating that glucose-restricted effector T
cells reprogramed their metabolism by switching from aerobic glycolysis to OXPHOS
(Figure 11C). Cells maintained in 1mM glucose for an additional week continued to
use OXPHOS over glycolysis. While we observed diminished cell population
expansion after culturing in 1mM glucose media compared to 25mM glucose media
(Figure 11D), cell survival was maintained (Figures 12B). Altogether, these data
suggest that exposing activated T cells to glucose limiting conditions can induce a
functional state of hyporesponsiveness in a persisting population of T cells.
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§ 3.3 The hyporesponsive phenotype of T cells restricted from glucose cannot
be fully restored by re-exposure to glucose

We previously observed that defects in cytokine production of TILs isolated from
glucose-restrictive tumors could not be fully recovered even in the presence of
sufficient glucose during re-stimulation (Chang et al., 2015). Our findings here show
that glucose-restricted T cells are able to survive and proliferate, but have impaired
IFN-γ production due to insufficient glycolysis in vitro. We questioned whether
restoring glucose levels would rescue their hyporesponsive phenotype. In order to
test this, we re-exposed glucose-restricted T cells to 25mM glucose for 24h and
analyzed their proliferation and cellular metabolism as well as effector cytokine
production. The addition of glucose rescued the dampened IFN-γ production of T
cells after acute glucose starvation, which re-engaged in glycolysis (Figures 11A
and 11C). T cell expansion was also restored when sufficient glucose was present
(Figure 11D). However, glucose failed to correct the status of hyporesponsive T
cells subjected to prolonged glucose restriction (Figure 11A and 11C). We observed
not only continued impairment of T cell expansion, but also defects in IFN-γ
production were no longer restored by additional glucose when cultured in 1mM
glucose for 6 days. T cells experiencing long-term glucose restriction gradually lost
the ability to re-engage in glycolysis, resulting in irreversible dysfunction of effector
cytokine production (Figures 11A and 11D). Interestingly, glucose supplementation
did not significantly change the surface expression of PD-1 on glucose-restricted T
cells compared to non-treated cells (Figure 11B).
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Figure 11. Prolonged glucose restriction limits T cell IFN-γ production that
cannot be rescued by glucose re-expose
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Naïve OT-I T cells were activated with OVA peptide for 3 days in high glucose media
(25mM glucose and 10%FCS). T cells were either maintained in 25mM glucose (Glc)
media or switched to low glucose condition (1mM glucose and 10%FCS) followed by
re-exposure to 25mM glucose for 24h. Cells were collected at day 5, day 7 and day 9
for analysis. (A) IFN-γ production of T cells were examined after 5h re-stimulated
with PMA/ionomycin. FACS plots are representative of >7 independent experiments.
Numbers show relative MFI of IFN-γ producing cells normalized to 25mM glucose
group as the mean ± SEM. *p=0.016, **p=0.006, **p=0.004, **p=0.008. (B) PD-1
expression of T cells was assessed by flow cytometry and data from ≥5 independent
experiments are shown in bar graph as relative MFI normalized to T cells cultured in
25mM glucose media. **p=0.0029, ****p<0.0001. (C) ECAR (left) and OCR/ECAR
ratio (right) of T cells in differentiate glucose media. Data are from 6 independent
experiments presented as relative ECAR or OCR/ECAR ratio normalized to T cells in
25mM glucose media. ***p=0.0004, **p=0.006, *p=0.022, *p=0.025 (ECAR),
***P=0.0007, **P=0.002, *P=0.05, *P=0.01, *P=0.03. (D) The cell expansion was
measured using a haemocytometer and data are presented as fold change over 24h
culture. Bar graph are obtained from 4 independent experiments and shown as
±SEM, ****p<0.0001, *p=0.0125, *p=0.0185, **p=0.003.
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Figure 12. Glucose restriction does not impair T cell survival in vitro

(A) The schematic diagram of in vitro culture system. (B) The viability of culture T
cells in differentiated glucose culture media was measured by the haemocytometer
with Trypan blue staining. The data is presented as the bar graph from >=4
independent experiments.

94

§ 3.4 Glucose availability regulates Glut-1 expression, which directly controls
glucose uptake by T cells

Given the described role of the glucose transporter Glut-1 in controlling glucose
uptake during T cell activation (Frauwirth et al., 2002, Frauwirth and Thompson,
2002, Scheepers et al., 2004, Jacobs et al., 2008), we assayed the total protein level
of Glut-1 in differentially cultured T cells by western blot and found that cells exposed
to 1mM glucose dramatically induced Glut-1 expression compared to those in 25mM
glucose conditions (Figure 13A). Glucose-restricted cells did not maintain this high
level of Glut-1 expression at later time points as observed by decreased total protein
levels. Importantly, cells experiencing acute glucose restriction could respond to reexposure of exogenous glucose and subsequently decreased their expression of
Glut-1, but also became refractory to added glucose over time (Figure 13A).
Quantification of Glut-1 mRNA exhibited a similar expression pattern (Figure 13B).
Acute glucose deprivation led to an elevation of Slc2a1 (Glut-1) mRNA, which was
not observed under long-term glucose restriction. Accordingly, 2-NBDG (2-(N-(7Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose) incorporation by T cells
supported these results showing that glucose-restricted T cells with upregulated
Glut-1 expression had an increased ability for glucose acquisition. However, T cells
cultured under prolonged glucose restriction were unable to mediate sufficient
glucose uptake in response to lower Glut-1 expression (Figure 13C). Interestingly,
the protein level of another glucose transporter Glut-3, which is also expressed by T
cells but is not essential for T cell function (Macintyre et al., 2014), was not
modulated by glucose availability (Figure 14). Our results suggest that glucose
availability in the extracellular environment dictates expression of the glucose
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transporter Glut-1 on T cells, which may be responsible for their inability to engage
glycolysis for optimal cytokine production.
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Figure 13. Prolonged glucose restriction decreases surface Glut-1 expression
and prevents efficient glucose uptake

(A) Total Glut1 expression in T cells with glucose restriction was examined by
western blot, and data are representative of ≥2 independent experiments. (B) mRNA
level of Glut-1 was analyzed by qPCR. Data from 2 independent experiments are
relative quantity of mRNA normalized to T cells cultured in 25mM glucose media and
presented as ±SEM. *p=0.013. (C) T cells in differentiate glucose media were
cultured in 5ug/ml 2NBDG at RT for 15min and 2NBDG uptake was measured by
flow cytometry. Representative histogram plots are shown on the left and relative
mean fluorescence intensity (MFI) of 2NBDG shown on the right was normalized to
the MFI of cells cultured in 25mM glucose media. Bar graphs are shown as ±SEM
and from ≥3 independent experiments. ***p=0.0004, **p=0.003.
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Figure 14. Glut-3 expression maintains the same regardless of glucose
perturbation

Total protein expression of Glut-3 of T cells in glucose restriction condition was exanimated
by western blot. Data is the representative image from 2 independent experiments.
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§ 3.5 Acetate rescues IFN-γ production of T cells under prolonged glucoserestriction

Since supplementing glucose failed to restore IFN-γ production of T cells exposed to
prolonged glucose-limiting conditions, and our data suggested that this could be due
to the inability to acquire glucose due to dysregulated Glut1 expression, we asked if
there might be alternative metabolites that could potentially play a role in modulating
T cell function. Acetate has been recognized as an important alternative carbon
source for cancer cells to support their survival and proliferation in glucose starvation
(Hosios and Vander Heiden, 2014, Lyssiotis and Cantley, 2014). In addition to
cancer cells, recent studies also indicate a critical role for acetate in immune cells
such as macrophages and memory T cells during metabolic stress (Kendrick et al.,
2010, Balmer et al., 2016). In order to investigate whether acetate can enhance
effector T cell function depressed by prolonged glucose-limitation, we treated cells
with 5mM sodium acetate instead of additional glucose for 24h and measured
intracellular IFN-γ protein after PMA and ionomycin restimulation. Significant
enhancement of IFN-γ production was observed not only in T cells exposed acutely
to low glucose media, but also in those that became unresponsive to additional
glucose cultured under prolonged glucose restriction (Figure 15A). These data
suggest

that

unlike

glucose,

the

metabolite

acetate

can

hyporesponsiveness of T cells induced by long-term glucose starvation.
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§ 3.6 Acetate is incorporated into histones and enhances histone acetylation in
glucose-restricted T cells

In order to be utilized by cells, acetate must be enzymatically converted to acetyl
coenzyme A (acetyl-CoA), which is essential for a vast majority of biological
processes including protein acetylation and lipogenesis. In human livers, acetate
converted acetyl-CoA enhances histone acetylation at promoter regions of
proinflammatory genes in residential macrophages (Kendrick et al., 2010). AcetylCoA derived from acetate can also acetylate the glycolytic enzyme GAPDH, which is
important for optimal function of memory CD8 T cells under stress (Balmer et al.,
2016). According to these findings, we reasoned that the augmentation of IFN-γ
production by acetate maybe a consequence of histone acetylation, which promotes
gene expression, and not necessarily due to GADPH modification, since glycolysis is
severely dampened in glucose-restricted T cells. Indeed, we were able to observe a
dramatic increase in IFN-γ production when using valproic acid (VPA), which is a
histone deacetylase inhibitor and results in increased levels of histone acetylation
(Figure 15A).

Acetate can enter cells through monocarboxylate transporters (MCTs) or facilitated
diffusion via aquaporins (Kirat and Kato, 2006, Kirat et al., 2006, Halestrap and
Wilson, 2012, Rae et al., 2012). After penetrating the membrane, acetate is
catalyzed to acetyl-CoA in an ATP-dependent manner (Watkins et al., 2007). The
mammalian genome contains genes encoding three different acetyl-CoA synthetase
enzymes capable of converting acetate to acetyl-CoA, one of which, designated
ACSS2, has been reported to be localized to both the cytoplasm and nucleus and is
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required for acetate uptake and utilization (Fujino et al., 2001, Perez-Chacon et al.,
2009, Comerford et al., 2014). We wondered whether T cells were still competent for
acetyl-CoA generation from acetate in glucose-limiting conditions. Western blots
assessing the protein level of MCT-4 as well as ACSS2 revealed that the membrane
transporter and catalyzing enzyme responsible for cellular acetate uptake and
utilization were consistently expressed, regardless of glucose concentration in the
media (Figure 15B), unlike Glut-1, the expression of which is modulated by glucose
availability (Figure 16A).

To test whether T cells use acetate for histone modifications, we assessed the
incorporation of acetyl groups into histones by exposing cells to
The radioactivity count of
without

14

14

14

C labeled acetate.

C was enriched in extracted histones compared to those

C labeled acetate treatment (Figure 15C), suggesting that T cells were

able to take up exogenous acetate and catalyze it into intermediate metabolites.
Another major role of acetate metabolism is to generate acetyl-CoA in cytoplasm for
lipid synthesis. The incorporation of

14

C labeled acetate into lipid compartments

further confirmed the ability of glucose-restricted T cells to uptake and utiliize
exogenous acetate (Figure 16B).

Next we extracted histones from glucose-

restricted T cells and measured global acetylation of histones by western blot. As
expected from our radiolabeled studies and consistent with previous reports
(Kendrick et al., 2010, Lee et al., 2014, Shen et al., 2015, Shi and Tu, 2015), we
observed significantly elevated acetylation on histone proteins H3 and H4 in acetate
treated T cells during glucose restriction (Figure 15D). We also found that ACSS2
expression was increased by the addition of acetate, which is consistent with
previous reports that acetate consumption is dictated by functional expression of
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ACSS2 (Figure 15D) (Comerford et al., 2014). Accordingly, the quantification of
mRNA expression of the IFN-γ gene significantly increased in T cells exposed to
acetate compare to non-treated group, which supports our hypothesis that
augmentation of histone acetylation enhances cytokine gene expression and thus
reverses the hyporesponsive phenotype of T cells subjected to nutrient stress
(Figure 15E).
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Figure 15. Exogenous acetate enhances IFN-γ production from T cells during
prolonged glucose restriction in an ACSS2 dependent manner
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(A) Naïve OT1 T cells were activated as descried before and treated with 5mM
sodium acetate or 1mM valproic acid for 24h. IFN-γ production of T cells was
measured 5h after PMA/ionomycin re-stimulation. Dot plots showing MFI of IFN-γ as
the representative of >=5 independent experiments and bar graph is presented as
relative MFI of IFN-γ+ cells normalized to untreated cells. *p=0.034, **p=0.006,
****p<0.0001 (Acetate), *p=0.013, ****p<0.0001, **p=0.006. (B)

T cells are

differentially cultured in the media containing 0, 0.1,1,5,10 and 25mM glucose. The
expression of ACSS2 and MCT-4 enzymes were exanimated by western blot at day
5,7 and 9 post-activation. (C) Cultured T cells were assayed for their ability to utilized
[14C]acetate for histone acetylation. Bar charts are shown as mean ± SEM (error bar)
from ≥2 independent experiments. (D) Global histone acetylation was measured
western blot and graphs are shown as representative of >=2 independent
experiments. (E) IFN-γ mRNA was analyzed by real-time quantitative PCR and
relative expression of mRNA of each time point and culture condition over the levels
expressed in untreated cells and data presented as ±SEM.

104

Figure 16. Glucose restricted T cells maintain the ability for acetate uptake

(A) The expression of membrane bond Glut-1 in T cells cultured in differentiated glucose
condition was also exanimated by western blot. Data is the representative image from 2
independent experiments. (B) The incorporation of [14C]acetate into lipids was measured
and Bar charts are shown as mean ± SEM (error bar) from ≥2 independent experiments.
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§ 3.7 The effect of acetate on enhancing IFN-γ production is dependent on
ACCS2

Based on evidence that ACSS2 is the primary enzyme that converts cytosolic
acetate to acetyl-CoA, which can be used by histone acetyl transferases for histone
acetylation, we reasoned that the rescue of cytokine production driven by acetate
would be dependent on ACSS2. In order to test this hypothesis, we used shorthairpin RNAs to selectively silence ACSS2. Suppression of ACSS2 by shRNA
rendered glucose-restricted T cells unresponsive to acetate-induced increases in
IFN-γ production compared to control cells, indicating a requirement of ACSS2 for
acetate in rescuing cytokine production in glucose-restricted T cells (Figure 17A).
The knockdown efficiency of ACSS2 protein was confirmed by western blot (Figure
18B). Furthermore, we measured incorporation of acetyl units into histonse or lipids
by exposing transduced T cells with

14

C acetate and found that T cells with reduced

ACSS2 enzyme exhibited an impaired ability to utilize radiolabeled acetate and
assimilate it in both histone and lipid components (Figure 17C and 18). Together,
our data suggest that ACSS2 is important for allowing T cells to respond to
exogenous acetate by converting it into acetyl-CoA for subsequent metabolic
utilization and chromatin modification.
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§ 3.8 ACSS2 is required for optimal effector T cell function in vivo

As reported previously, systemic acetate concentrations present in serum are
transiently increased under metabolic stress induced by bacterial infections in mice
(Balmer et al., 2016). The observation that hyporesponsive T cells with prolonged
glucose restriction maintained ACSS2 expression to be able to process exogenous
acetate instead of glucose led us to consider the importance of ACSS2 for antigen
specific T cell responses during infection or cancer. In order to address this question,
we took advantage of EL4 lymphoma tumors expressing OVA antigen (EL4-OVA)
and OT-I T cells that recognize OVA. We injected 1x106 EL4-OVA cells
subcutaneously and then intravenously transferred 5x106 activated OT-I cells
expressing either control or ACSS2-shRNA into Thy1.1+ recipient mice 5 days posttumor transplantation (Figure 17C). XX days later we measured Donor OT-I T cells
in the peripheral blood and found that cells expressing ACSS2-shRNA exhibited
dampened IFN-γ production after restimulation compared to those expressing the
control hairpin (Figure 17D). Although mice that received activated OT-I T cells
were able to control tumor growth, tumor clearance was impaired in mice that
received OT-I T cells expressing the ACSS2-shRNA (Figure 17E). These data
indicate that antigen specific T cell effector function can be affected by the loss of
ACSS2 in vivo due to its inability to utilize endogenous acetate under metabolic
stress (Figure 18C).
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Figure 17. ACSS2 is important for effector T cell function in vivo.
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(A) OT-1 T cells transduced with either control Luc shRNA (Luc-hp) or constitutive
shRNA knockdown of ACSS2 (ACSS2-hp). IFN-γ production of transduced T cells
treated with acetate or VPA was measured 5h after PMA/ionomycin restimulation.
Bar graph showing fold change of IFN-γ MFI was normalized to 1mM Glc control
group from 1 experiment. (B) Their ability to incorporate [14C]acetate into histone
was also assayed and data presents the mean± SEM and n=3. (C) 1x106 EL4-Ova
lymphoma cells were s.c. injected into C57BL/6 Thy1.1+ congenic mice that received
5x106 transformed OT-I Thy1.1+ CD8+ T cells containing control Luc-hp or Acss2-hp
5 days post tumor transplantation. (D) Mice were bled 7 days post-transplantation
and IFN-γ production of donor transduced T cells was assessed after overnight OVA
peptide re-stimulation. FACS plot showing MFI of IFN-γ as the representative of 2
mice and dot graph of of from 2 independent experiments and dot graph is presented
as percentage and MFI of IFN-γ+ cells (n>=10). *p=0.0343. (E) Tumor growth was
monitored and data are an average of two perpendicular diameters ± SEM. (n≥4).
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Figure 18. The incorporation of acetate into cells and thus drive IFN-γ
production is mediated by ACSS2.

(A) OT-1 T cells transduced with 4 different short hairpin against ACSS2 and IFN-γ
production of acetate or VPA treated T cells were measured 5h after PMA/Ionomycin
re-stimulation. (B) The knock-down efficiency of short hairpin against ACSS2 were
confirmed by western blot. (C) The incorporation of [14C]acetate into lipid in
transduced T cells were assessed and bar graph in shown as the relative CMP
normalized to control Luc-hp from 3 independent experiments. ***p=0.0004.
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§ 3.9 PDL-1/PD-1 signals promote ACSS2 expression and enhance T cell
responsiveness to acetate

The PDL-1/PD-1 signal pathway has been recognized as one of many inhibitory
mechanisms that contribute to T cell hyporesponsiveness during infections and
cancer (Barber et al., 2006, Day et al., 2006). Higher and sustained expression of
PD-1 is a hallmark of hyporesponsive T cells, which mediate downstream signaling
cascade that dampen T cell function (Odorizzi and Wherry, 2012, Okazaki et al.,
2013). We showed here that glucose-restricted T cells with defective cytokine
production augment PD-1 expression on the cell surface in our in vitro model. From
a metabolic aspect, PD-1 can alter T cell metabolism by promoting fatty acid
oxidation and inhibiting glycolysis, thus preventing optimal effector function
(Patsoukis et al., 2015). As a result, PD-1 blockade may induce metabolic
reprogramming by enhancing cellular glycolysis in order to reinvigorate their function.
New studies on exhausted or hyporesponsive T cells with high PD-1 expression
suggest a distinct but stable epigenetic profile, which indicates a potential limitation
of current PD-1 pathway blockade immunotherapies to reverse their dysfunctional
state (Pauken et al., 2016). In line with our finding that acetate can rescue cytokine
production in T cells with prolonged glucose restriction through histone modification
in an ACSS2 dependent manner, we considered the possibility that elevated PD1
signaling may have an effect on mediating cellular responses to alternative nutrients
such as acetate when available glucose is insufficient.

In order to test this

hypothesis, we applied recombinant PDL-1 antibody (rPDL1) to induce PD-1 signals
on T cells. Surprisingly, we observed increased protein expression of ACSS2 in a
dose dependent manner. Upregulation of ACSS2 was also observed on cells after
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administration of acetate (Figure 19A). Accordingly, significantly more cells
produced IFN-γ in response to acetate supplementation when exposed to rPDL1
(Figure 19B). These data suggest that PDL-1/PD1 signals modulate ACSS2
expression on T cells, which promotes their ability to utilize acetate to potentially
enhance cytokine production.
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Figure 19. PDL-1/PD-1 signals promote ACSS2 expression in T cells, which
contributes to the cellular response to acetate

(A) in vitro activated T cells were treated with recombinant PDL-1 protein along with
either PBS or acetate for 24h and protein level of ACSS2 enzyme was measured by
western blot. The graph is representative of 2 independent experiments. (B) IFN-γ
production of T cells was examined after 4h re-stimulated with α-CD3 and α-CD28
antibodies. Data is shown as mean ± SEM and n=4. **p=0.007, *p=0.03, **p=0.009.
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§ 3.10 Discussion

Access to sufficient nutrient depots is critical for effector T cell function. T cells must
acquire nutrients to engage appropriate metabolism to support their functions to fight
against infection and cancer (Chang et al., 2013, Pearce et al., 2013, Buck et al.,
2015, O'Sullivan and Pearce, 2015). Our group and others have highlighted a model
of nutrient competition, whereby glucose depletion by tumors in the tumor
microenvironment in vivo can lead to T cell hyporesponsiveness despite the
presence of robust antigens recognized by T cells (Mellor and Munn, 2008, Mockler
et al., 2014, Chang et al., 2015). However, simply re-exposing hyporesponsive T
cells isolated from a progressing tumor to glucose ex vivo cannot rescue dampened
cytokine production. In order to understand how T cells sense and adapt to a
glucose-depleted environment, we established an in vitro model and demonstrate
that glucose restriction limits cellular glycolysis of T cells and dampens their ability to
produce IFN-γ. While this defect in cytokine production can be reversed after initial
short-term glucose restriction, it cannot be reversed by glucose re-exposure when T
cells undergo prolonged glucose restriction. Our data suggest that this inability to
respond to glucose associates with the eventual down-regulation of Glut-1
expression, which directly prevents efficient glucose uptake even in glucose replete
conditions. Glut-1 has been reported to be selectively essential for T cell activation
and effector function despite the expression of other glucose transporters, such as
Glut-3 (Macintyre et al., 2014). In line with this finding, we also observed that Glut-3
is constantly expressed, independent of exogenous glucose level. Availability of
nutrients and other metabolites, growth factors, and costimulatory signals that dictate
whether T cells will express appropriate transporters to allow nutrient acquisition, will
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impact T cell function in vivo. However, a fundamental understanding about how
different glucose transporters are differentially regulated and facilitate T cell
responsiveness to glucose in vivo remains a subject of ongoing investigation.

Research in cancer metabolism for the last decade has greatly extended our
understanding of the metabolic requirements of proliferating cells, as well as
metabolic alternations that promote cell growth. As a primary energy resource,
glucose plays an essential role in supporting cellular bioenergetics and maintaining
normal cell function. When transiting to environments with limiting nutrients and
oxygen, cancer cells reprogram their metabolism to cope with environmental
changes in a manner dependent on alterative substrates, as do immune cells. We
found that acetate, a unique metabolite positioned at the intersection of metabolism
and epigenetic regulation, enhances IFN-γ production from T cells during prolonged
glucose restriction. The maintenance of MCT expression, as well as the enzyme
ACSS2, independent of glucose availability suggests that T cells maintain the ability
to acquire and utilize acetate in situations when glucose becomes limiting. It is
possible that the observed enhancement in cytokine production is the result of
differential expression of ACSS2 in the nuclear compartment, which is specifically
responsible for histone acetylation as suggested by studies in cancer cells under
serum and oxygen limiting conditions (Bulusu et al., 2017). Together with our results
that PDL-1/PD-1 signals regulate ACSS2 levels suggest that, acetate metabolism
presents a distinct target for reinvigorating responses from dysfunctional T cells.

In summary, we have shown that prolonged glucose restriction contributes to T cell
hyporesponsiveness characterized by defects in IFN-γ production, which cannot be
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corrected by simple re-exposure to glucose. However, administration of acetate can
rescue cytokine production of T cells in an ACSS2 dependent manner. We also
demonstrate a role of PDL-1/PD-1 signal in regulating ACSS2 expression, which
may present as an alternative mechanism for preserving effector T cell function in
vivo. Understanding nutrient competition in the microenvironment and ways of
enhancing T cell nutrient acquisition should be considered in the generation of future
therapies in order to promote optimal T cell immunity.

116

CHAPTER 4

SUMMARY AND FUTRUE REMARKS
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§ 4.1 Summary

It has long been appreciated that, unlike bacteria or yeast, which respond directly to
nutrients in their environment, mammalian cells must be instructed by growth factors
in order to efficiently utilize nutrients. This presents a fundamental mechanism for the
regulation of cell growth in metazoans. One of the classical examples of this it how
IL-2 promotes glucose transports expression for mediating glucose uptake. It is also
equally important to consider that available nutrients, substrates, or other resource
may also become limited or immune cell niches, affecting immune cell metabolism
and thereby, cell function and fate.

A well-characterized example of this is

tryptophan catabolism by tumors or antigen presenting cells negatively affects
infiltrating T cell function and survival. Moreover, competition for arginine that rapidly
depleted by myeloid-derived suppressor cell populations may also fall into this
general category.

Given these findings, it would seem likely that substrate

availability, whether concentrations of nutrient itself or of the growth factors that
allows its acquisition, fluctuates dramatically depending on the location of the
immune cells. By using the MCA-induced sarcoma tumor cell line, we have been
able to demonstrate a general nutrient competition model in which glucose
consumption by antigenic tumors can metabolically restrict T cells, directly
dampening their effector function and allowing tumor progression. Checkpoint
blockade therapy may present a way to correct this nutrient imbalance through a
direct effect in the tumor cells.

However, our further study suggests that the plasticity of T cell response to
additional glucose dynamically changes overtime. Simply re-expose T cells with
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prolonged glucose restriction cannot fully restored effector T cell function, which may
due to its inability of regulating the expression of glucose transporters for the
sufficient nutrient uptake. Taking lessons from cancer metabolism that cancer an
cells derive energy from alternative carbon sources and metabolic pathway to
maintain cell survival and proliferation under nutrient limiting conditions, we
considered the opportunities by the utilization of fatty acids, amino acids, ketone
bodies and acetate in addition to glucose for therapeutic manipulation. Given the
central role of acetyl-CoA in cellular metabolism, acetate has garnered increased
attention in the context of cancer as both an epigenetic regulator of posttranslational
protein modification, and as a carbon source for cellular biomass accumulation. Our
data suggest that unlike glucose, metabolism acetate can rescue T cell
hyporesponsiveness under prolonged glucose restriction. The augmentation of
cytokine production by acetate is dependent on acetyl-CoA synthesis enzyme
ACSS2 through histone acetylation enhancement.
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§ 4.2 Future remarks

Our initial observation that limiting glucose condition dampens cellular glycolysis in T
cells thus impairs their effector function. However, the primary data suggests that
glucose-restricted T cells do not increase the utilization of glutamine or lipids to
compensate the shortage of glucose. Further studies on glucose tracing and
quantification of metabolites should be conducted to understand the metabolic
plasticity of T cells under metabolic stress. Moreover, glucose restricted T cells
upregulates glut-1 expression, which coordinates with increased glucose uptake.
However, this increased ability of glucose acquisition did not help compensate their
dampened cellular glycolysis. Exactly how T cells regulate the surface nutrient
transporter and how the expression of these transporters associates with the whole
cell metabolism in response to environmental cues thus affect their function need to
be addressed.

One of our novel findings is that the presentation of acetate can rescue impaired
cytokine production in T cells with prolonged glucose restriction dependent on
ACSS2 enzyme. However, there are two other isoforms encoded by the genes in the
same family ACSS2, which locate in the mitochondria and differentially expressed in
terms of tissue distribution. Although it has been reported that ACSS1 and 3 are not
as important as ACSS2 to convert acetate to acetyl-CoA for energy derivation in
cancer cells, the contribution of these enzymes to acetate metabolism T cell in the
glucose limiting condition has not well characterized. Given that acetate incorporate
into TCA cycle and contributes to the cellular acetyl-CoA pool, mitochondrial enzyme
ACSS1 and 3 could potentially play a role in T cell metabolism as well as their
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function under metabolic stress. Further studies are required to investigate this
hypothesis.

T cell hyporesponsiveness described in chronic infections or cancer is usually
marked by elevated surface PD-1 expression. The ligation of PD-L1 with PD-1 can
transmit a negative signal to T cells thus inhibit its function. PD-1/PD-L1 pathway
presents one of the inhibitory mechanisms that contribute to impaired effector T cell
function. We Surprisingly found that PDL-1 induced PD-1 signals in glucose
restricted T cells could modulate ACSS2 expression, which promote their ability to
response to acetate. Beyond the well-appreciated PD-1/PDL1 signaling, our study
might suggest a distinct role of PD1 plays during T cell hyporesonsiveness.
However, the underlying mechanism of how PD-L1/PD-1 pathway involved in
contributing T cell response to alternative nutrients and how that affected T cell
functions in nutrient restricted environment requires further investigated.

Because cellular metabolism is linked to immune cell function, understanding more
about metabolic pathway in T cells will likely illuminate new ways to exploit these
pathways to harness immunity in vivo. Our studies have provided new insights
regarding the contributions of primary as well as alternative carbon sources to T cell
metabolism and function in the tumor microenvironment. With the appreciation for
the role of metabolism in dictating immune cell function, our research could result in
revolutionary effective immunotherapies by targeting metabolism to prevent T cell
dysfunction in cancer.
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CHAPTER 5

MATERIALS AND METHODS
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§ 5.1 Mice and tumor cells
129S6 mice from Taconic Farms and C57BL/6, C57BL/6 CD90.1 and major
histocompatibility complex (MHC) class I-restricted OVA specific TCR OT-I
transgenic mice from The Jackson Laboratory were used for all experiments.
Animals were housed in our specific-pathogen free animal facility and studies were
performed in accordance with procedures approved by the AAALAC accredited
Animal Studies Committee of Washington University School of Medicine in St. Louis.
An established methylcholanthrene (MCA)-induced mouse sarcoma model of
regressing (d42m1-T2 or R tumor) and progressing tumors (d42m1- T3 or P tumor)
were used in this study, both of which originated from d42m1 parental sarcoma cells
(Matsushita et al., 2012). Other progressing tumor clones (T10, ES1, ES2, and ES3)
derived from the d42m1 parental sarcoma cells were kindly provided by Dr. Robert
Schreiber. B16 cells, L cells and MC38 cells were kindly given by Dr. Marco Colonna
and were used for anti-PD-L1 blockade antibody treatment experiments.

§ 5.2 Tumor Transplantation
For the sarcoma model, 1-2x106 R or P tumor cells unless otherwise indicated were
injected subcutaneously (s.c.) in 150 µl of sterilized PBS into the right flank of mice.
Recipient mice were 6-8 week old males on the 129S6 background. Tumor size was
measured and quantified as the average of two perpendicular diameters. For the
EL4-Ova model, a total of 1x106 or 40x106 EL4-Ova cells were injected into the
peritoneal cavity of recipient C57BL/6 wild-type (Thy1.2+) mice. Splenocytes from
naïve OT-I Thy1.1+ mice were stained with Kb/OVA tetramer to determine the
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proportion of OVA-specific CD8+ T cells. Splenocytes containing 2x104 naïve
Thy1.1+ OVA-specific CD8+ T cells were transferred intravenously (i.v.) to the
recipient mice on the same day of EL4-Ova tumor transplantation.
For ACSS Knock-down experiment in EL4-Ova model, a total of 1x106 EL4-Ova cells
were subcutaneously (s.c.) in 150ul sterilized PBS into right flank of recipient
C57BL/6 Thy1.1+ mice. Splenocytes from naïve OT-I Thy1.2+ mice were activated by
OVA peptides and transduced with either control Luc-hp or Acss2-hp. Transformed
OVA-specific CD8+ T cells were transferred intravenously (i.v.) to the recipient mice
5 days post EL4-Ova tumor transplantation. For the sarcoma model, 1x106
progressing tumor cells unless otherwise indicated were injected subcutaneously
(s.c.) in 150 µl of sterilized PBS into the right flank of the mouse. Recipient mice
were 6-8 week old males on the C57BL/6 background. Tumor size was measured
and quantified as the average of two perpendicular diameters.

§ 5.3 Tumor harvest
Established sarcoma tumors were excised from mice at ~12 days posttransplantation. Isolated tumors were chopped and treated with 1 mg/ml type IA
collagenase (Sigma) and DNase I (Sigma) in HBSS (Hyclone) for 1h incubation at
37°C. In order to keep phosphorylated proteins stable, tumor harvest was performed
at 0–4°C. Cells were filtered through a 70-micron strainer to obtain single-cell
suspensions.
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§ 5.4 In vivo checkpoint blockade treatment
Tumor bearing mice were treated intraperitoneally (i.p.) with 200 µg of anti-CTLA4
(9H10) or anti-PD-1 (clone RMP1-14) or anti-PD-L1 (clone 10F.9G2) on days 3, 6,
and 9 post-tumor transplantation. Tumor bearing mice in the control group were
injected with 200 µg each of IgG2a and IgG1 isotype antibodies.

§ 5.5 Flow cytomoetry and intracellular staining
All fluorochrome-conjugated monoclonal antibodies were purchased from BioLegend
or eBioscience, except Alexa Fluor® 647-conjugated phospho-4E-BP1 (Thr37/46),
Alexa Fluor® 488-conjugated phospho-S6 ribosomal protein (Ser235/236), and
phospho-p70 S6 kinase (Thr389) antibodies (Cell Signaling). Intracellular cytokine
staining was performed as previously described (Chang et al., 2013). Briefly, cells
were stimulated at 37°C for 5h in complete medium supplemented with 100 U/ml IL2 and 1.0 µl/ml GolgiStop (BD Pharmingen) with or without PMA and ionomycin
(Sigma). After stimulation, cells were fixed in Cytofix/Cytoperm fixation (BD
Biosciences) at 4°C for 20 min before intracellular staining. Staining for
phosphorylated signaling proteins was carried out with Phosflow kits (BD
Biosciences). Ex vivo bulk tumors were directly fixed with Phosflow Lyse/Fix buffer
(BD Biosciences) at RT for 10 min and then permeabilized on ice for 30 min before
intracellular staining. Tumor infiltrating CD8+ T cells (TILs) represent cells gated on
CD45+TCRβ+Thy1.2+CD8+ and tumor cells were gated on CD45-FSChi. CD45+TCRβ+
Thy1.2+CD4+ cells were gated as CD4+ T cells, CD45+CD19+ cells as B cells, and
CD45+CD64+F4/80+ cells as macrophages. Macrophages expressing iNOS were
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referred to M1 type and those expressing RELMα referred to M2 type. For 2-NBDG
uptake in vivo, mice were injected i.v. with 100 µg 2-NBDG/mouse diluted in PBS.
For proliferation assay, cells were fluorescein-labeled with 5 µM CellTrace Violet
(Life Technologies) at 37°C for 30 min. Anti-PD-L1 antibody (clone MIH5) was used
to detect surface PD-L1 expression on tumor cells. Data were collected on
FACSCalibur (BD Biosciences), FACSCanto II (BD Biosciences), LSRFortessa (BD
Biosciences) and analyzed by FlowJo software (TreeStar).

§ 5.6 Cell culture
R-tumor-specific CTL clone (C3) cells were kindly provided by Dr. Robert Schreiber
and maintained by co-culturing with irradiated d42m1 parental sarcoma cells. C3
cells were co-cultured for 24h with or without sarcoma tumor cells at different ratios
as indicated. Cultured cells were supplemented with or without 25 mM glucose
during PMA/ionomycin stimulation and cytokine production by T cells was analyzed
by intracellular staining. For in vitro antibody treatment assay, tumor cells were
treated with 100 U/ml of recombinant murine IFN-γ (PeproTech) for 24h following by
10 µg/ml anti-PD-L1 treatment for an additional 24h before further experiments. All
tumors were cultured in RPMI 1640 media containing 10% FCS. Naïve CD8+ T cells
were isolated from spleen and lymph nodes of 129S6 mice, and purified by MACS
microbeads (Miltenyi Biotec). T cells were stimulated with 0.5 µg/ml anti-CD28 and
100 U/ml IL-2 in 5 µg/ml anti-CD3 coated plates for 3–4 days. Activated CD8+ T cells
were used for the experiments as indicated in the main text.
Naïve T cells were isolated from spleens and lymph nodes of OT-1 transgenic mice
and activated with ovalbumin peptide SIINFEKL. T cells were cultured in no glucose
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PRMI 1640 media containing 10% FCS and additional 25mM glucose was added
during 3d activation and then switch to the media containing 1mM glucose for 1, 3
and 5 days. Cells were plated at same concentration everyday when fresh media
was supplied. Cultured cells were supplemented with glucose, acetate and valproic
acid for 24h as indicated concentration in the main text. Cytokine production by T
cells was analyzed by intracellular staining after 5h PMA/Ionomycin re-stimulation.

§ 5.7 Metabolism assay
Real-time oxygen consumption rates (OCR) and extracellular acidification rates
(ECAR) were analyzed by a XF96 Extracellular Flux Analyzer (Seahorse
Bioscience). Cells were plated in nonbuffered RPMI 1640 media with 10 mM
glucose. Measurements were obtained under basal conditions and after the addition
of 1 µM oligomycin (an inhibitor of ATP synthase).

§ 5.8 Glucose assay
Supernatant from tumor and T cell co-culture experiments was collected, and
glucose concentrations were measured by Glucose Assay Kit (Eton Bioscience). For
determining glucose levels in established tumors, harvested tumors were weighed
and minced in fixed amounts of PBS. Ex vivo glucose concentration was quantified in
accordance with the weight of tumors and the volume of collected supernatant, and
normalized with glucose concentrations in the R tumor.
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§ 5.9 Transduction
For knocking-down PD-L1 expression, sarcoma tumor cells were transduced with
GFP-reporting virus expressing shRNA against luciferase (Ctrl hp), or virus
expressing shRNA against CD274 (PD-L1 hp) in media containing 8 µg/ml
Polybrene (Sigma) and 20 mM HEPES (Hyclone) for 5h, followed by additional
transduction with the same virus overnight. Transduced tumor cells were sorted by
GFP expression on a FACSAria II (BD Biosciences). For overexpression, R tumor
cells were transduced with retrovirus expressing c-Myc (R-cMyc), or PDK1 (RPDK1), or with empty vector only (R-EV Ctrl), and puromycin was used to select for
stably transduced tumor cells. R tumor cells with differential PD-L1 expression were
kindly provided from Dr. Robert Schreiber. They were generated by retroviral
transduction and subcloned according to their surface PD-L1 expression.
For knocking-down ACSS2 expression, OT-1 T cells were transduced with GFPreporting virus expressing shRNA against luciferase (control), or virus expressing
shRNA against Acss2 (Acss2 hp) in media containing 8 µg/ml Polybrene (Sigma)
and 20 mM HEBES (Hyclone). Cells were spinned down at 2500rpm for 90min at
30°C followed by additional transduction with the same virus overnight. Transduced
T cells were sorted by GFP expression on a FACSAria II (BD Biosciences).

§ 5.10 RT-PCR and western blotting
Total RNA was isolated with the mRNeasy mini kit (QIAGEN) and cDNA was
synthesized with the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). All quantitative RT-PCR was performed by the Taqman method, except
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for mutant spectrin-β2 mRNA, which was assayed by the SYBR green method, with
an Applied Biosystems 7500 sequence detection system. For detecting the
expression of mutant spectrin-β2, RNA was isolated as described above. After RTPCR amplification, cDNA fragments were cut by restriction enzyme Pst1 and
analyzed by electrophoresis as described (Matsushita et al., 2012). For western
blotting,

cell

lysate

preparation,

SDS–PAGE,

electrophoretic

transfer,

immunoblotting, and development using enhanced chemiluminescence were
accomplished as previously described (Pearce et al., 2009). All antibodies for
western analysis were purchased from Cell Signaling, except Triosephosphate
isomerase (TPI) from Abcam and Phosphoglycerate kinase 1 (PGK1) from Thermo
Scientific.

For

detecting

mTOR

pathway

signaling,

antibodies

against

phosphorylation of 4E-BP1 (p4EBP1) at Thr37/46, p70 S6 kinase (pS6K) at Thr389,
and S6 ribosomal protein (pS6) at Ser235/236 were used. For detecting AKT
signaling, antibody against phosphorylation of AKT (pAKT) at Ser473 was used. For
detection of histone acetylation, cells were lysed with PBS containing 0.5% Triton X
100 (v/v), 2mM phenylmethylsufonyl fluoride (PMSF) and 0.02% NaN3 followed by
acid extraction by 0.2N HCl overnight. Antibodies against total H3 and H4 were from
Cell Signaling but acetyl-histone H3 and acetyl-histone H4 were purchased from
EMD Millipore.

§ 5.11 Detection of PD-L1 internalization
R tumor clones overexpressing high levels of PD-L1 was treated with αPDL1 antibody (αPD-L1) for 15 min on ice, then either kept on ice or incubated at 37°C
for 30 min. The cells were then either washed in an acid-strip solution (0.2M acetic
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acid, 0.5M NaCl) twice to dissociate antibody from the surface of the cells or left
untreated. After fixation in 4% paraformaldehyde for 10 min, cells were incubated
with Alexa Fluor® 488-conjugated (A488) anti-Rat IgG antibody to detect αPD-L1
present on the surface of the cells. Then, following permeabilization (Perm/Wash;
BD Biosciences), the cells were incubated with Alexa Fluor® 647-conjugated (A647)
anti-Rat IgG antibody to detect both surface expressed and internalized αPD-L1.
Surface and internalized PD-L1 were then assessed by flow cytometry. Following
staining with a nuclear stain (DAPI), cells were mounted in anti-fade (Prolong
Diamond; Life Technologies) and imaged by confocal microscopy.

§ 5.12 [14C]Acetate incorporation into histones and lipids
For histone incorporation, cells were treated with 1µCi/ml sodium [1,2-14C] acetate
(PerkinElmer) for overnight. After two washes with ice-cold PBS, cell pellets were resuspended in 500µl NP-40 buffer (0.1% NP-40, 10mM HEPES, 5mM MgCl2, 0.25M
Sucrose) and incubated on ice for 10min. Lysates were washed with buffer without
NP-40 and spun down at 6000g for 10min. Histone were acid extracted in 500µl of
0.8M HCl overnight with shaking and then centrifuged at 4°C 20,000xg for 30min.
Supernatants were neutralized with 40ul of 10N NaOH and counted for radioactivity
using Ultima Gold scintillation fluid.
For lipid incorporation, cells were treated with 1µCi/ml sodium [1,2-14C] acetate
(PerkinElmer) for overnight. After two washes with ice-cold PBS, cells were lysed
with 0.6ml MeOH solution. 0.4ml CHCl3 was added to lysate and vortexed for 30s.
Lysates were then centrifuged for 5min at 1000rpm for phase separation. Soluble
lipid fraction was collected at lower layer and counted for radioactivity.
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§ 5.13 Statistical analysis
Comparisons for two groups were calculated by using an unpaired, two-tailed
Student’s t-test. Comparisons for more than two groups were calculated using 1way ANOVA followed by Bonferroni’s multiple comparison tests.
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